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The development of external stimuli responsive nanoparticles has progressed 
greatly since its inception in the seventies.  However, apart from some clinical success for 
slow release delivery via liposomes, the technology has stalled for the delivery of 
chemotherapeutics due to a myriad of problems with cytocompatibility and premature 
diffusion of drug payload.  
The solution to cytocompatibility has been the coating of the system with 
polyethylene glycol. New methods have been developed to attach polyethylene glycol 
(PEG) tethers to the surface of otherwise unreactive particles.  Surface hydrolysis of 
acrylamide containing polymers can be used to produce carboxylic acid functional groups 
near the surface of the polymeric nanoparticles.  These nanoparticles can then be 
functionalized with PEG via EDC/NHS chemistry. The use of surface hydrolysis not only 
allows for reaction with these neutral polymers, but also provides greater control of PEG 
localization and leads to an unintrusive method to add the much needed stealth coating.   
  In order to address the issue with premature release, new polymer systems have 
been developed. These systems are based around theory of hydrophobic interaction in 
vi 
order to improve the polymer/drug interaction in order to limit the unwanted diffusional 
release of drug payload. This interaction was addressed in a number of ways, focusing on 
both compartmentalization and copolymerization in order to develop nanogels that can 
entrap and withhold more drug from the surrounding area.    
An in depth look into the interactions that encourage drug uptake in these systems 
was performed by altering the copolymer chosen for these systems.  This work looks into 
effects on phase transition, functional groups, hydrophobicity, and any structural changes 
that occur as a result of the polymerization scheme.   
After drawing conclusions on the interactions that encourage drug uptake, 
complex systems were devised to take advantage of these interactions.  Core shell 
systems were designed to take advantage of the convective release of lower critical 
solution systems while still utilizing the mechanisms that improve drug retention. These 
systems were synthesized by two methods, emulsion polymerization and micelle 
crosslinking.  These systems have been showed to improve the drug interaction and 
retention of doxorubicin as a model chemotherapeutic.     
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Chapter 1 
Introduction 
Externally triggered theranostic delivery schemes are an attractive treatment method for 
localized diseases with devastating treatments.  The beautiful marriage between therapeutic and 
diagnostic technologies allows for improved treatment, granting physicians added control and 
providing real time data about the progress of the disease and treatment[1]. The primary disease 
focus for these systems in the past has been tumorous cancers. Cancer is an ideal disease for 
these systems due to the natural accumulation of particles due to the fenestrated vasculature 
allowing for particle accumulation and the devastating effects of the treatment as well as the 
disease[2].     
Current treatment for tumorous cancers involves surgery, radiotherapy, chemotherapy, or some 
combination of the three. For localized tumors surgery is often the best form of treatment, 
excising the tumor before the cancer can spread to the surrounding tissue.  However, cancer is 
rarely caught when surgery is capable of completely curing the disease, and surgery can be 
debilitating calling for one of the other two major treatments[3].   
Radiotherapy uses focused radiation to damage and kill cancer cells, often times damaging the 
healthy cells surrounding the neoplasm.  Radiotherapy can be effectively targeted with some of 
the newer radiation technology, such as proton beam therapy, though the overall success is still 
limited.  Until the fabled “magic bullet” is developed, cancer will continue to be a disease that 
requires multiple modes of treatment.  In this vein, more work must be done to provide doctors 
every possible improvement to help them better treat cancers while limiting the often devastating 
side effects. 
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These side effects can be limited by localizing the drugs to cancerous areas. Localization of 
chemotherapeutics can aid treatment by limiting off site effects, increasing the level of drugs 
delivered, and ensuring their unabated delivery to the target area.  This technology can increase 
doctors’ ability to maintain chemotherapeutic drugs within the therapeutic range.  Development 
and optimization of this technology will be an important step in improving the chemotherapeutic 
aspect of cancer treatment.        
 
Externally triggered theranostic devices are comprised of four major components: a visualizable 
and external stimuli responsive core, a stimuli sensitive coating, biocompatible stabilization 
coating, and a targeting moiety.  This thesis will focus on the synthesis and interaction of the first 
three components with a brief discussion on the inclusion of the targeting moiety.  For the 
purpose of this work this technology will be based around temperature sensitive hydrogels 
encasing magnetic nanoparticles.   
 
These systems can provide an important tool for doctors as they battle the wide variety of 
cancers that exist.  However, there are a number of questions to answer about these systems, not 
limited to the investigation of the interaction of all of the components necessary to develop a 
fully functioning composite system. 
24 
 
Chapter 2: Background 
Externally triggerable theranostic drug delivery vehicles offer a solution to the problem with 
non-specific drugs.  Externally triggered drugs allow for the localization of drugs and eliminating 
the issues that can arise from systemic delivery; such as toxicity and unnecessary off site effects. 
However, due to the complex nature of these treatments these nano-devices are not 
recommended for chronic diseases.  With these considerations there are a few diseases that 
would lend themselves well to theranostic delivery.  They are HIV; a disease that, in the early 
stages, can be treated with anti-retrovirals[4], and Cancer; for which chemotherapeutic treatment 
provides a long list of devastating side effects[3].   
 
The majority of this work has focused on the use of these composite nanoparticles for the 
treatment of cancer. Due to the fenestrated vasculature, the deleterious off site effects, and the 
already complex nature of the treatment, Cancer is an ideal target for the development of this 
technology.   
2.1 Cancer and its Treatment 
Cancer is a difficult disease to identify; each presentation of the disease has different 
physiological and chemical characteristics, even when the disease is structurally similar.  This 
has led to treatments that have a broad spectrum of effect, killing or removing all of the cells in 
their radius of impact.  Until recently, the only three methods for treatment have been surgery, 
chemotherapy, and radiation therapy.  Recent advances in targeted protein based treatments have 
shown some slight success, however they are specialized in the types of cancer they treat and can 
still require the other forms of treatment for noticeable success[3].  Until further progress is made 
the original three treatment methods are necessary.  
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Surgery has so far proven the most effective of completely removing cancers, when this is an 
option.  Often, the tumors grow in sensitive areas or are noticed too late for surgery to be a viable 
option for the eradication of the cancer. This leaves patients dependent on radiotherapy and 
chemotherapy, both of which have devastating side effects.  Much research has been developed 
to limit these undesirable effects for radiotherapy, with recent advances in proton beam therapy.  
This technology allows for improved accuracy of the beam limiting the damage to the cancerous 
region[5].  Similar work has been looked to for chemotherapy, however much work is still 
needed to perfect it.   
 
In order to do this, researchers looked for a commonality among cancer types to exploit. 
Although different types of cancer have a wide range of physical and chemical markers, research 
has identified a few common characteristics that are present in most tumors.  The most attractive 
of which is the leaky vasculature caused by the increased angiogenesis[2].  The astounding rate 
at which tumors grow requires rapid and, subsequently, faulty development of vasculature in 
order to supply blood to the foreign tissue. This fact results in the phenomenon known as the 
enhanced permeability and retention (EPR) effect.  Essentially, this states that the leaky 
vasculature common to most tumors allows for the increased uptake of large molecular weight 
drugs[2].  This form of passive targeting has been pursued for years as a mechanism to treat 
cancer. 
 
Nanoparticles have been looked to as a means to prevent the side effects caused by the systemic 
application of chemotherapeutics by passively targeting to the site of the tumor via the EPR 
effect[6].  One of the common issues encountered with these nanoparticles is the accumulation in 
the liver and other tissues with vasculature similar to tumors[7]. There are a few methods to limit 
this off target accumulation. The simplest of these methods is difference in particle size. Some 
studies have proven that, with some cancer types, by increasing the size of gold and liposomal 
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nanoparticles over the normally affirmed 100 nm particle size; in the range of 150-300 nm[8, 9].   
 
The issue with this is that it is not universal among all cancer lines.  Much as the differences in 
cancer genetics can lead to large differences in genetic markers, it also can lead to differences in 
the endothelial lining, with no real pattern to describe the differences in the fenestrations leading 
to particle uptake[6].  Another mechanism is altering the hydrophobicity/hydrophilicity of the 
particles.  Research has shown that hydrophobic particles are more likely to accumulate in the 
liver and removed by other parts of the reticuloendothelial system (RES)[6, 10].  The common 
method to accomplish this is to graft polyethylene glycol (PEG) to the surface.  This unique 
molecule allows for the stealthing of particles, though this is not a perfect solution for the 
undesired accumulation in the liver, though it can limit this problem[5].   
 
The method that shows the highest level of improvement is to affix some form of active targeting 
to the nanoparticles. Among all cancer types, the inclusion of an appropriate targeting moiety can 
increase the accumulation in the tumor, thus limiting its presence in other tissues[6]. However 
each cancer type must be targeted by a different moiety, leading to specialized particle drugs 
being needed.  To this extent many targeting moieties have been attempted to be identified for 
their use with nanoparticles, with the most promising being anti-enhanced growth factor receptor 
(EGFR)[11].  However, the issue with these antibodies is that they tend to activate the growth of 
the cancer, leading to a growth increase before triggering.  Before particle based systems are 
widely and freely applied a better option for active targeting needs to be identified.  
Current Methods for Particle Based Chemotherapeutic Delivery 
The predominant methods for particle based drug delivery fall into four major categories: 
 
 
Liposomes 
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Polymeric Micelles  
Dendrimers 
Hydrogel Nanoparticles 
 
2.1.1 Liposomal Drug Delivery 
The only clinically-approved particle based drug delivery of chemotherapeutics for many years 
has been Doxil
©
, a PEGylated liposome for the delivery of Doxarubacin (DOX)[5]. Doxil
©
 is a 
liposomal drug carrier that contains tightly packed DOX inside a single bilayer of a combination 
of lipids and cholesterol like molecules.  This is the simplest design of such particle based 
delivery vehicles, as it serves as only a carrier for the hydrophobic drug molecules, using only 
the EPR effect to localize the drug to the cancerous region.    
 
Liposomal drug delivery has turned to the use of stimuli responsive lipids in order to increase 
control of drug release while also providing diagnostic tools.   Temperature sensitive liposomes 
composed of cholesterols and the temperature sensitive lipid, hydrogenated-L-α-
phosphatidylcholine, have been combined with nanoparticles and large molecules that can be 
triggered via external stimuli and monitored.  The in vitro release of these drugs were examined 
and proven that the release rate is dependent on temperature, and maximum release is achieved 
in a relatively harmless range of 38-40 ºC[12, 13].  However, these advances are limited, as 
significant drug release is still seen at physiological temperatures.  However, their ability to be 
triggered by ultrasound triggered small molecules, such as Gd(HPDO3A)(H2O), is a unique 
technique for liposomes[12]. 
 
Liposomes that respond to changes in pH have also been examined as delivery vehicles for 
chemotherapeutics. Two methods have been used in order to take advantage of these liposomes. 
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The first is using the intracellular pH change that occurs between cancerous regions and regions 
of healthy tissue, a drop from 7.4 to about 6.5.  However, this drop is not consistent and is often 
used in addition to another response, such as thermosensitive or perhaps a second pH 
responsiveness[14].  This has been achieved by combining pH sensitivity with a pH sensitive 
hydrolyzeable linker between the liposome and PEG.    
 
The other mechanism utilizes endosomal uptake and release in order to trigger a pH shift.  In 
order to enhance uptake of neutral liposomes a ligand specific to cancer cells, anti-CD-19, has 
been affixed to pH sensitive liposomes in order to trigger internalization of the particles.  Once in 
the endosome, the pH response was triggered, and the drug payload was successfully released.  
However, these particles still struggled with premature payload release[15]. This mechanism 
utilizes Dioleoylphosphatidylethanolamine (DOPE) or a thiol-PEG modified istearoylphosphati-
dylethanolamine (DSPE). DOPE is naturally pH responsive, breaking apart lipid bilayers as the 
pH drops to about 5.5.  PEG modified DSPE requires the presence of reducing agents that are 
readily available inside cells.  
 2.1.2 Polymeric Micelles  
Polymeric micelles are normally amphiphillic block copolymers that form stable micelles due to 
hydrophobic domains.  With the advancements of block copolymerization, tri-block copolymers 
have even been formed to provide multiple stimuli responsive sections to attempt to provide 
extra barriers to drug release. Multi-responsive micelles have been developed with a variety of 
sensitivities; including temperature, pH, electromagnetic, and oxidative stress[16]. 
 
Micelles are only held together by the hydrophobic effect, partitioning the water insoluble and 
water soluble sections in order to limit the enthalpic effects.  A common micelle involves block 
copolymers composed of polystyrene and a stimuli responsive block, eg. acrylic acid. The issue 
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encountered with micelles, is their sensitivity to changes in solution characteristics, such as ionic 
strength and pH.  These sensitivities lead to unstable micelles that can begin to disassociate in 
the blood stream before reaching the target[17].  
 
In order to improve the stability of the micelles, electrostatic interactions have been used.  The 
ionic molecules are water soluble, but by combining oppositely charged polymers of similar 
length the block copolymers can form micelles due to association[18].  However, studies have 
shown that ionic block copolymers mixed with large molecules; eg amino acids or calcium ions, 
complexation is not dependent on the similar length postulate[19, 20].  Systems that are 
stabilized by the presence of Calcium ions can even be cross-linked by the addition of ethylene 
diamine tetraaetic acid[20].   
 
Micelles sensitive to ultrasound have also been developed in order to provide external control 
over the delivery of the drug payload. In these studies a drastically hydrophobic core polymer 
was used, allowing for phase differentiation between the drug containing core and the 
surrounding aqueous environment[21].  The ultrasound release mechanism depends only on the 
sensitive nature of the micelles existence.  To this point, the accumulation of the micelles has 
been entirely dependent on the EPR effect and the accuracy of the ultrasound waves.  The 
pharmacokinetics have proven this an effective means for turmor treatment[22]. 
Dendrimers 
Dendrimers are branched polymers that can be formed by three main mechanisms; convergent, 
divergent, and convergent/divergent, describing the method by which the sections of the 
dendrimer grow together (CITE).  Dendrimers have shown some ability to naturally retain model 
chemotherapeutics, however covalently attaching the chemotherapeutics has proven more 
effective for the delivery of DOX via dendrimer[23, 24].  By attaching the drug with a 
30 
 
chemically liable linker, the drug can be contained until it reaches the destination with the 
necessary conditions to detach the drug.     
 
Dendrimers are classified by their generation and their functional side group.  The majority of 
dendrimers used for the delivery of chemotherapeutics are poly(amido amines), that produce 
amine terminated sequences[25].  Generation describes the number of consecutive reactions 
completed, essentially counting the rings from the origin.  Each successive generation produces 
more functional groups and an increased size depending on the function of synthesis.  For 
poly(amido amines) each successive generation doubles the number of free amines and increases 
the diameter of the particle[25]. 
 
Dendrimers have proven capable of dual payload delivery when two half dendrimers are joined 
to form a Janus dendrimer[26].  More impressively, these systems have proven capable of 
controlling the ratios of drugs delivered based upon the respective generation of the two halves.  
This capability could prove an effective mechanism for delivering drug pairs with    
2.1.2  Hydrogel Nanoparticles 
Hydrogel nanoparticles are composed of water soluble cross-linked polymers that swell in the 
presence of water. Poly(lactic-co-glycolic acid) is the common system that is both biocompatible 
and biodegradeable[27].  Hydrogels are often stimuli responsive, being composed of a polymer 
that undergoes a critical transition in response to a change of solution characteristics or a stimuli 
response, eg electromagnetic [28].  For the purpose of the delivery of chemotherapeutics, the 
majority of the research has been on temperature sensitive polymers in conjunction with another 
stimuli responsive inorganic particle[29, 30].  Like dendrimers, hydrogels can be produced with 
functional groups to which drugs can be conjugated to with a liable bond.  Again, the issue with 
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these systems for the delivery of chemotherapeutics is identifying a bond that is unique for 
cancerous tissue.   
  
2.2 Thermoresponsive Hydrogels for Externally Triggered Drug Delivery 
Externally triggered drug delivery depends on the development of composite nanoparticle 
systems responsive to some form of external stimuli.  These systems are often composed of a 
temperature sensitive polymeric shell and a core that heats in response to an external stimulus, as 
seen in Illustration 2.1.  Further surface modification is necessary in order to allow these things 
to flow through the bloodstream without to be attacked by the body’s immune response [27].  
Finally a targeting moiety is necessary in order to improve targeting to the tumorous area.   
 
Research into these responsive systems has largely focused on systems of polymers that display 
lower critical solution temperatures (LCSTs) in water, largely due to the early development of N-
Isopropyl acrylamide (NIPAAm).  However, there have been a few upper critical solution 
temperature (UCST) responsive polymers developed that have been reproduced in nanoscale 
systems.  The issue encountered with these UCST systems, particularly those with 
physiologically relevant responses, is the presence of ionic functional groups that render these 
systems overly sensitive to ionic conditions[31].  For example, one of the more prevalent UCST 
systems developed by Okano is a interpenetrating polymer network (IPN) of acrylic acid (AA) 
and acrylamide (AAm)[32].  This system displays a UCST of 39ºC, but only under very specific 
ionic and pH conditions.  Shifting away from these temperatures results in loss of swelling 
response altogether.    
 
As far as LCST responsive systems, there are a variety of them that demonstrate temperature 
responses at or around the physiological temperature of 37ºC.  These are mostly N-Alkyl 
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substituted acrylamides and their copolymers.  NIPAAm is the original system to demonstrate 
the unusual response in water near physiological temperatures.  For many years, research has 
attempted to shift the LCST response of NIPAAm polymers from its response of 32ºC by a 
number of copolymers and IPN networks[33].  One such successful system involves the 
copolymerization with 2-acrylamido-2-methyl-1-propanesufonic acid (AMPS). The sulfonic acid 
groups provide the necessary temperature response, however, it also provides a group sensitive 
to the ionic and pH shifts that can occur between patients[34].  
 
Several neutral copolymers have been examined, and proven to shift the transition temperature 
above 37ºC, most promising of which is acrylamide.  However, when this system is 
copolymerized into a gel, the higher levels of acrylamide lead to decreases in overall changes in 
swelling volume[35].  The addition of acrylamide is an attractive prospective, as it entails the 
addition of a completely neutral monomer, that has a swells independent of most solution 
conditions.   
 
Other polymers have been developed based off of the success of NIPAAm, focusing mostly on 
finding ways to alter the N substituted acrylamides. By altering the alkyl group that extends from 
the nitrogen the transition temperature can be shifted, again, potentially limiting the overall 
swelling response.  One system that shows promise is another isopropyl modified acrylamide. 
The simple addition of a methyl group to the vinyl carbon, creating N-Isopropylmethacrylamide 
(NIPMAM), significantly alters the transition temperature to above, to 45ºC [36].  This transition 
temperature has left a response well above physiological temperature which could lead to 
unwanted hypothermia[30].  In order to avoid this, the LCST of pNIPMAM must be depressed.  
This has been accomplished with NIPAAm polymers by the addition of a hydrophobic 
comonomer, such as butyl methacrylate[37].   
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These polymer systems can be tuned to show different properties, however the issue encountered 
is the foreign body response to these nanoparticles.  In order to overcome this response a stealth 
coating is necessary.  This leads to the necessity of a PEG coating in order to limit the RES from 
removing the particles before their arrival at the tumor and the subsequent release [27].  The 
issue with these neutral polymers is the only way to provide a PEG coating is to graft the PEG 
into the backbone.  This method is problematic, as the grafting of PEG limits the swelling 
response of the polymer system[38]. However, these systems lead to many of the same problems, 
the statistical implementation of PEG chains into the thermoresponsive pNIPAAm chains results 
in loss of temperature sensitivity, particularly at concentrations necessary to limit the protein 
adhesion that leads to opsonization[27]. 
 
Core-shell systems were the next step in order to improve loading and release control.  A number 
of systems have been developed along these lines, coupling thermosensitive polymers with a 
range of other stimuli sensitive polymers[39].  The predominant combination for delivery of 
chemotherapeutics is the combination of temperature and pH responsive systems, trying to take 
advantage of the acidic nature of tumorous areas in the body.  Both cationic and anionic pH 
responsive systems have been successfully incorporated into what are known as “schizophrenic” 
micelles.  These systems are identified as schizophrenic due to the ability to reverse the 
aqueous/non-aqueous phases by manipulation of pH and temperature.  Anionic systems focus 
primarily around AA like polymers. These systems collapse as the pH drops below the critical 
point[40]. This leads to a double pumping mechanism for the release of a drug payload.  
However, it can also lead to limiting the release at lower pHs, which is not advantageous for 
chemotherapeutic delivery.   
 
Cationic pH sensitive polymers could prove to be more promising, as the drop and pH will lead 
to a positive swelling response that will result in improved diffusion only in the cancerous area.  
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For this purpose, N'N' Dimethyl aminoethyl methacrylate (DAMEMA) This is a promising 
prospect, yet drug loading and delivery has not yet been performed on these complex systems, let 
alone with the inorganic nanoparticles necessary for the external temperature triggering[40]. 
2.3 Precipitation Polymerization 
Nanogels composed of NIPAAm and other LCST free radical polymers are often synthesized via 
a technique known as precipitation polymerization. This technique is a two phase system, a 
continuous phase, water, and as surfactant stabilized spherical micelle phase.  All of the reactive 
species are present in water at a temperature well above the transition point.  As the 
polymerization proceeds, the temperature sensitive polymer precipitates out of the continuous 
phase into the micelle phase. Chains in both phases continue to grow and terminate leading to the 
production of spherical nanogels[41].      
2.4 Stimuli Responsive Nanoparticles for Hyperthermia 
2.4.1 Magnetic Nanopartices 
Magnetic nanoparticles (MNPs) can be divided into four categories, diamagnetic, paramagnetic, 
ferromagnetic, and superparamagnetic.  Each of these types of particles responds to magnetic 
fields in different ways due to the way their electrons occupy and move about different orbital 
spins. Similarly, their response to heating via alternating magnetic fields (AMFs) can yield 
drastically different results.  However, superparamagnetic nanoparticles are often chosen, 
superparamagnetism is dependent on a combination of ferromagnetic domains and temperature 
high enough to overcome the energy required to do so.  This switching can be utilized by an 
AMF to induce massive heating for the size of the particles [42].  Magnetic nanoparticles can be 
synthesized from a number of base materials, including iron, cobalt, nickel, and alloys thereof.  
For biological applications iron oxide nanoparticles are preferred since the body is naturally 
capable of breaking them down into nontoxic materials[43].  
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 Magnetic nanoparticles provide an imaging moiety, as they have proven to be useful as MRI 
contrast agents.  As magnetic nanopartilces accumulate in a specific area, the reflexive response 
time of magnetically aligned protons in that area decreases.  By visualizing this data with a heat 
map the nanopartilces can be localized.  This, combined with the EPR effect and a targeting 
mechanism, leads to an effective mechanism for visualizing and identifying cancerous tissue[44].  
This can be combined with the hyperthermic abilities can lead to theranostic particle systems. 
2.4.2 Gold Nanorods 
Gold nanoparticles have been developed and pursued due to the phenomena known as surface 
plasmon resonance, caused by the surface oscillations of electrons.  This phenomena allows for 
the visualization of gold particles, and even allows for heating in response to pulsed lasers.  
However, these lasers are often in the UV-visible spectrum, which is effectively filtered out by 
human skin.  To overcome this, gold nanorods were developed, which respond to wavelengths in 
the near infrared spectrum.  These wavelengths are more effective at penetrating human skin, and 
thus a more effective system for intravenous drug delivery[45].  
 
The one advantage that gold nanorods have over their magnetic counterparts is the precision with 
which they can be heated.  The lasers used for gold nanorods can be targeted heating specific 
tissues, unlike the coils necessary for heating magnetic nanoparticles.  This adds another level of 
targeting to further control the delivery of chemotherapeutics.  However, this comes at a cost of 
cytocompatibility.  At low levels gold particles are harmless, but as they accumulate in the body 
due to lack of a clearance mechanism the concentration builds to dangerous levels.  Some 
coatings have done a great deal to improve this, but there is still a toxic level achievable by 
repeated treatments[46].              
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2.5 The Thermodynamics of N-Alkyl Substituted Acrylamides 
The LCST of N-alkyl substituted acrylamides arises from a balance of enthalpic and entropic 
forces. Hydrogen bonds between the water and carbonyl groups of the polymer provide enthalpic 
benefits while the increase in organization they require results in increased entropy. As the 
temperature increases the balance between the enthalpic and entropic effect results in the LCST 
phase transition as the water/polymer system phase separates to decrease the entropy of the 
system.        
2.6 Effects of Ionic Species  
The development of NIPAAm like polymeric drug vehicles has required the use of ionic 
surfactants that interact in peculiar ways with the responsive polymers.  There have been many 
investigations into the impact of surfactants on the LCST response of these hydrogels.  As the 
collapse is initiated the surfactant begins to stabilize the transition, leading to a peak in the 
absorption of the surfactant into the hydrogel. This surfactant stabilization on its own is 
relatively harmless, with no change in swelling response when the same studies were performed 
with non-ionic surfactant.  However, the ionic species included with SDS leads to changes in 
swelling response and LCST[47].   
 
This reaction is easily explained when examining the effect of free ions in the solution.  The 
inclusion of ions depresses the LCST and increases swelling response.  This is a function of the 
interference of the water cages that are necessary to balance the hydrophilic and hydrophobic in 
an aqueous environment.  The presence of these ions interferes with these water cages resulting 
in a decrease in the enthalpic contribution. This leads to a depression of the LCST and an 
increase in the ΔT.  However, when the ions are kosmotropic the interaction is more complex 
resulting in two LCST responses, though the impact on the LCST still follows the same 
trend[48].   
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Illustration 2.1: Drawing of thermoresponsive nanocomposite loaded with model drug.
 
1. Temperature sensitive 
polymeric nanoparticle 
2. Surface Grafted Poly ethylene 
glycol(PEG)/ targeting ligand 
3. Effective loading and 
controlled release of 
chemotherapeutic 
4. Gold/Magnetic Nanoparticle 
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CHAPTER 3 
 Objectives 
The overall objective of this work is to develop a full composite system for the externally 
controllable release of model chemotherapeutics.  In order to achieve this objective this work is 
divided into categories in order to overcome many of the problems that are encountered with 
these systems.  In that ilk the two major problems have been identified as biocompatibility and 
the polymer/drug interaction.  This work will attempt to identify solutions to both of these issues 
and then bring them together with the other pieces of these nanocomposites to examine their 
impact on the system as a whole.   
 
For the biocompatibility issue the solution that is necessary is addressing the complexities 
involved in the inclusion of long polymer chains of PEG to these stimuli responsive particles.  
This work will attempt to provide a solution to this problem that is both simple and effective.  
This work will depend heavily on the success of comonomer incorporation, and identifying a 
critical surface PEG concentration necessary to stealth these particles.  
 
The bigger issue with these systems is the premature release of drug payload due to the poor 
drug/polymer interaction.  Since the loading and retention of drugs in these systems is mostly 
dependent on diffusion, improving the partitioning of drugs into these hydrogels would be a big 
step in improving the loading and release.  However, due to the aqueous nature of hydrogels.  In 
order to address this issue the drug/polymer interaction aspect of this work will be broken down 
into two sections.  First the inclusion of comonomers will be examined in order to see if a simple 
mechanism exists to improve drug uptake and retention, this will be covered in Chapter 5.  
Second, a complex core/shell system will be developed in attempt to provide a temperature 
sensitive pumping mechanism inside a drug compatible core. 
39 
 
 
The core shell system will further be divided into to methodologies to achieve this solution. First 
will be a traditional sequential free radical polymerization in order to grow the shell on the core, 
and will be discussed in chapter 6.  The second method will be the development of amphiphilic 
hydrophobic/hydrophobic/hydrophilic block copolymers that will be cross-linked after self-
assembly into micelles, the topic of chapter 7.              
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CHAPTER 4 
 Surface Hydrolysis Mediated PEGylation of P(NIPAAm-co-AAm) Nanogels 
4.1 Background 
The application of nanoparticles to intravenous drug delivery depends greatly on the circulation 
half-life. This is a necessity for particles of all types, as their increased size leads to their 
immediate attack via the RES.  Systems based on functionalized amides, such as NIPAAm, are 
stable to the point of not being able to react with many of the functional PEG groups available, 
requiring the addition of a reactive comonomer.  However, the inclusion of these functional 
groups results in significant modification of the temperature response, and potentially introduces 
undesirable pH sensitivity[6].   
 
In order to overcome the problems inherent with the copolymerization of many of these PEG 
comonomers and  other charged functional groups we turn to a copolymer that has proven to 
both have little to no pH responsiveness as well as a positive impact on the swelling response of 
NIPAAm based nanogels.  P(NIPAAm-co-AAm) nanogels prepared at a molar feed ratio with 
15%-20% AAm were shown to increase in the overall swelling response; at the same time the 
LCST was shifted up to 37- 39ºC [35].   
 
AAm is susceptible to is hydrolysis, under extreme pH and temperatures AAm can be converted 
to AA in the presence of water.  Under normal conditions this is not beneficial, as it leads to the 
distribution of AA throughout the nanoparticle. The syneresis of PNIPAAm can be used to 
protect the amide groups in the core of the particles.  This protection is attained by the expulsion 
of water, preventing hydrolysis. By triggering the response and then exposing the hydrogels to an 
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extreme pH, the AAm near the surface of the nanogel can be localized  due to the increased 
concentration of water at the surface[49].     
 
Hoare and Pelton have proven this result with P(NIPAAm-co-AAm) with AAm at a 10% molar 
feed concentration of the total monomer feed.  In their studies, they demonstrate the relative 
hydrolysis of P(NIPAAm-co-AAm) gels performed at 30ºC and 60ºC and a range of pH 
conditions.  Increasing temperature increases the rate and extent of hydrolysis; however they 
proved that the increased temperature resulted in lower hydrolytic conversion. The effect of 
titration speed was further proof that there was a localization of the hydrolyzed groups near the 
surface of the nanogels. As the speed of the titration of the 30ºC hydrolyzed system increased the 
concentration of carboxylic acid groups determined decreased.  Comparatively, the 60ºC 
hydrolysis sample showed no dependence on the rate of titration.  This result speaks to the 
dependence of ion diffusion into the nanogels.  Meaning the time scale of diffusion to the core of 
the particles is a significant burden. The critical titration step time is equivalent to the average 
depth of the functional group[49].   
 
This conversion of surface localized acrylic acid provides a simple mechanism for PEGylation 
with an amine terminated PEG and EDC/NHS chemistry.  This technique also lends itself to the 
concentration of PEG chains to the surface, limiting its impact on the overall swelling response 
of the nanoparticle.      
4.2 Materials and Methods 
4.2.1 Nanogel Synthesis 
NIPAAm from Scientific Polymer, Ammonium Persulfate (APS), AA, AAm N’N’-
Methylenebisacrylamide (MBAM), from Sigma Aldrich (St Louis, MO), and Sodium Dodecyl 
Sulfate (SDS) from Fisher Scientific (Pittsburgh, PA) were all used as received. In a standard 
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reaction NIPAAm, the comonomer (AA or AAm), MBAM, and SDS were mixed together in 
18.2 MΩcm water in the amounts specified in the table below for the 20% comonomer nanogels.  
This solution was purged for 30 minutes at 70ºC with Nitrogen under 200 rpm stirring with a 
football shaped stir bar in a round bottom flask.  Then APS dissolved in 18.2 MΩcm water was 
injected and the reaction was allowed to progress for 2 hours under constant stirring.  The 
reaction was then terminated by exposure to air.  Nanogels not destined for surface hydrolysis 
were then purified against 18.2 MΩcm water for two weeks with twice daily water changes then 
freeze dried.   
 
Component mol % of total solution % Monomer mol feed 
NIPAAm 0.020% 71% 
AAm or AA 0.0072% 20% 
MBAM 9.0x10
-5
% 9% 
SDS 1.9x10
-5
% NA 
Water 99.8% NA 
Table 4.1: Molar composition of nanogel synthesis. 
4.2.2 Surface Hydrolysis 
Sodium hydroxide and hydrochloric acid from Fisher Scientific (Pittsburgh, PA) were used as 
received.  Unpurified nanogel solution is heated to 60ºC and then mixed in equal volumes with 
1N sodium hydroxide.  This system was allowed to set for 3 days under constant stirring.  The 
solution was sonicated at 60ºC twice daily to break up aggregates.  At the end of 3 days an 
equivalent volume of 1N hydrochloric acid is added to bring down the temperature and pH 
simultaneously.  The pH is then adjusted with 0.1 N hydrochloric acid to a pH of 7.  The nanogel 
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product was then dialyzed against 18.2 MΩcm water for two weeks with twice daily water 
changes then freeze dried.   
4.2.3 EDC/NHS PEG Attachment    
N-Hydroxysuccimide (NHS) and 1-Ethyl-3-(3-dimethylamiopropyl)carbodiimide (EDC) from 
Thermo Scientific (Waltham, MA), and NH2-PEG from Lysan Bio. (Arab, AL) were all used as 
received.  In a standard reaction carboxylic acid containing particles were suspended in Borate 
buffer at a pH of 8.4 at a concentration of 4.7 mg/mL.  EDC and NHS were suspended in Borate 
buffer at a concentration of 25 mM and amine-PEG was suspended at a concentration of 20 mM.  
Then 3 parts particle solution, 3 parts PEG solution, and 2 parts NHS solution are mixed.  Two 
parts EDC solution is added and the solution is allowed to react overnight.  It was then dialyzed 
against 18.2 MΩcm water for 1 week with twice daily water changes to remove unreacted PEG 
and excess buffer then freeze dried. 
4.2.4 Zeta Potential and Swelling Measurements 
Zeta potential and particle size were measured using a Malvern Zetasizer ZS (Malvern, UK). The 
effect of temperature on swelling size was collected by dissolving freeze dried particles in 1 mL f 
DI water and adjusting the temperature by 3ºC increments and then allowed to equilibrate for 60 
seconds.  Temperature was ramped 20ºC-59ºC-20ºC to examine the effect of hysteresis on the 
samples particle size.   
4.2.5 Titrations 
Titrations are completed using an autotitrator (Hanna instruments HI902c, Carrolton, TX).  A 
known mass of nanoparticles were suspended in 5 mM KCl.  The samples were then auto-titrated 
with a 0.01N NaOH solution. The exact normality of the titrant was determined by titration of a 
known mass of potassium hydrogen phthalate.    
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4.2.6Protein Adsorption Studies 
To determine the effectiveness of the PEGylation reaction, these systems were incubated with 
model proteins, primarily Bovine Serum Albumin (BSA).  Unmodified, AA, and PEGylated 
particles were incubated at 1 mg/mL in a 10 mg/mL BSA/ 1X PBS solution at 37ºC and 45ºC to 
compare the protein adsorption of swollen and collapsed particles.  The particles and bound 
proteins were separated out via filtration through a 0.2 micron syringe filter, and their 
concentration left was determined by a micro BCA assay.   
4.2.7 TEM Microscopy 
Images were obtained on a Transmission Electron Microscope (FEI Tecnai, Hillsboro, OR)  
operating at 80 kV. Carbon coated copper grids (400 mesh) were plasma treated using an 
Emitech Glow Discharge instrument to render them hydrophilic prior to adding 5 µL of the 
nanoparticle suspension. After 30 seconds, the nanoparticle suspension was wicked off using 
Whatman 1 filter paper. The particles were negatively stained by placing a 5 µL drop of 2% 
uranyl acetate on the particle-coated grid for 30 seconds before being wicked off with Whatman 
1 filter paper. 
4.2.8 QCM Studies Protein Adsorption Studies 
A dynamic Quartz Crystal Microbalance (dQCM) (Q4, Biolin Scientific, Stockholm, SW)  was 
used.  In order to attach nanogels to the gold surface, first cysteine HCl was dissolved in a pH 8.4 
borate buffer and passed over the surface to form a gold-sulfur bond.  Then unattached cysteine 
was washed off.  Carboxylic acid containing monomers were then mixed with 25 mg of EDC 
and 25 mg of NHS in pH 8.4 borate buffer then immediately flowed over the cysteine coated 
gold surface.  Particles modified with PEG were synthesized as in the EDC/NHS PEG Attachent 
section above, only including a 1:10 ratio of sulfur-PEG-NH2 (Laysan Biotech, Arab, AL) to the 
PEG-NH2, both MW 2000.  These particles were bound by suspension in a Borate buffer, pH 8.4 
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then flowed over the gold surface.  Unattached particles were washed off with 1X PBS.  Particle 
modified surfaces then had a 10 mg/mL BSA solution in 1X PBS until saturation was obtained, 
signified by a constant Δf.  Then 1X PBS was flowed to wash off BSA not adsorbed to the 
particles.  
 
4.3 Results and Discussion 
4.3.1 Nanogel Copolymerization Synthesis and Swelling Response 
NIPAAm was copolymerized with 15%, and 20% of total monomer feed percentages of both 
AAm and AA.  The cross linker concentration (MBAM), was kept constant at 9% of the total 
monomer feed. Scanning electron microscope (SEM) images, seen in Figure 4.1, show the 
particles to be spherical.  The swelling responses for these systems can be seen in Figure 4.2 and 
Figure 4.3 for AAm and AA respectively.  Equilibrium swelling ratio (ESR) is defined as: 
𝐸𝑆𝑅 = (
𝑑
𝑑50º𝐶
)
3
 
The overall swelling response observed with 15 % AA is greater than that observed with AAm, 
however 20% AA significantly diminishes the swelling response while 20% AAm has no effect 
on the overall swelling response or the LCST.  These results demonstrate the need for utilizing 
AAm as the comonomer for PEGylation, as comonomer levels as high as 20% are likely 
necessary and with AAm no effects are seen on the swelling response up to this point.   
 
When 20% AAm is suspended in 1x phosphate buffered saline (PBS) an interesting phenomenon 
is observed as the temperature increases, as seen in Figure 4.4.  The left graph shows aggregation 
of particles as the temperature increases above 40ºC.  This effect is a function of an increase in 
the Van der Waals interactions being by the presence of ionic species.  The temperature sensitive 
nature of this effect is due to the discharge of water from the polymer system resulting in a 
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change in the average chemical makeup of the system.  This phenomenon is defined by the van 
der Waals net attraction parameter as seen in the  equations below[50]. 
𝑉𝐴 = −
𝐴𝑒𝑓𝑓𝑑𝑠
24ℎ
 
𝐴𝑒𝑓𝑓 = (𝐴𝑀
1/2
+ 𝐴𝑊
1/2
)
2
 
𝐴𝑀 = [𝐴𝑃
1/2
𝜙 + (1 − 𝜙)𝐴𝑊
1/2
]
2
 
Where ds is the diameter of the swollen gel, h is the separation of two particles, and Aeff is the 
Hamaker constant. The Hamaker constant for a hydrogel sphere is a function of the Hamaker 
constants of the polymer, water, and the volume fraction of the hydrogel.  As water is expelled 
the Hamaker coefficient increases closer to the value of PNIPAAm.  This leads to an increase in 
the magnitude of the van der Waals attraction, signifying the aggregation of particles.   
 
This phenomenon is entirely reversible, as raising and lowering the temperature returns the 
diameter of the particles to the same size in the DLS.  These results are promising for in vivo 
applications, as the particles will remain suspended swollen up to 40ºC, which is the desired 
response for these systems as the temperature response needs to be above physiological 
temperature. The physiological aggregation will likely also not be a problem due to lower 
concentrations and the pulsatile flow of the blood stream. 
4.3.2 Surface Hydrolysis and PEGylation 
The surface hydrolysis of P(NIPAAm-co-AAm) was confirmed by measurement of Zeta 
potential after each step of the process.  The results in Figure 4.5 show the Zeta potential results 
for 15% and 20% AAm formulations. The low initial magnitude of Zeta potential demonstrates 
the neutrality of the AAm polymer, with the only charge a symptom of surfactant that is 
necessary to stabilize the nanogels in solution. The Zeta potential greatly increases after the 
conversion of AAm to the anionic AA.  After PEGylation, the Zeta potential drops to a mild 
level, showing that the PEG tethers are shielding the charge of the nanoparticle.  Even though the 
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surface density of PEG tethers does not completely neutralize the Zeta Potential, it is still 
possible that the PEG tethers are able to efficiently stealth the particle. The negative charge 
measured could be due to the fact that the Zeta potential, in this instance, is measured by way of 
electrophoretic mobility.  This means that even though the surface might be neutralized, the 
presence of deeper ionic species still result in a response to the current applied by the Zetasizer.   
 
Figure 4.6 examines the temperature response of surface hydrolyzed 15% AAm and surface 
hydrolyzed 20% AAm.  Both nanogel compositions exhibited a swelling response similar to their 
unmodified counterparts in Figure 4.2 in the range of 37ºC to 60ºC, which is the temperature 
range that will likely be utilized in application.  The large error and unusual swelling response 
visualized up to 37ºC is potentially due to contaminates, though unlikely since the TEM 
micrographs show no signs of contaniments as seen in Figure 4.7.  It could also be an 
experimental artifact due to large swelling ratios and inconsistencies in refractive index due to 
the core/shell nature of these particles.  These inconsistencies are neutralized at higher 
temperatures as the particles begin their collapse. 
 
This could also simply be the function of the large error observed, as it has been shown by others 
in the lab that ionic species tend to have larger errors in their swollen state, although this is a 
larger extent of this error than previously observed.  These large error bars are troubling, 
however the swelling response from 37ºC to 45ºC remain intact, which is what is important for 
physiological application.   
 
After PEGylation, the AA functional groups get capped resulting in a decrease in overall 
swelling as a shell of non-temperature responsive PEG containing PNIPAAm groups gets 
functionalized.  However, the LCST remains unchanged and the swelling response is still 
sufficient for drug delivery purposes.  
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4.3.3 Carboxylic Acid Concentration  
The titration results, listed in Table 4.2, match the expected results based on the work by Hoare 
and Pelton [50].  The 20% AAm and AA systems obey the predicted values rather closely, 
though there is the slight chance that the AA experienced the mass transfer limited titration 
phenomenon observed by the Hoare and Pelton.  The result for 20% AAm could be a sign of 
hydrolysis beyond the surface, but the groups are probably still concentrated at the surface.  This 
is confirmed by the minimal impact this observed on the swelling response seen in Figure 4.8. 
 
Surface hydrolyzed 15% AAm studies followed the surface hydrolysis results closely, displaying 
a limited hydrolysis of only about 30% of the included AAm.  15% AA also demonstrates a 
limited inclusion of carboxylic monomers, as the titration indicates only 24% of the feed ratio is 
present in the final hydrogel.  Again, this discrepancy could be due to mass transfer limitations 
during the titration; however it is a fairly large discrepancy considering the 20% AA  system 
contained 72% of the feed ratio.   
 
The titration of surface hydrolyzed P(NIPAAm-co-AAm) with 20% AAm surface modified with 
PEG shows that the PEG reaction capped about 37% of the available carboxylic groups, which 
falls in line with the fact that EDC/NHS reaction was performed in a alkaline solution which 
favors activation of the PEG-amines.  This result matches the zeta potential measurements which 
show a drop of 45 ± 9% of the surface charge.   
4.3.4 Cytotoxicity 
These nanogels were measured for toxic impact against RAW 264.7 macrophages.  The results 
are shown in Figure 4.14.  These results show that none of the PNIPAAm based nanogels show 
any appreciable toxic effects, where all particles are statistically similar to the positive control up 
to a concentration of 1 mg/mL.   
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4.3.5 Protein Adsorption Studies 
The protein binding studies showed no significant effect of PEGylation between PEGylated and 
unmodified AAm containing copolymers.  However, there is significant reduction compared to 
its highly anionic counterpart, 20% AA.  These results also indicate a negligible protein 
adsorption at physiological temperature, as the results show statistically insignificant binding.  At 
higher temperatures the protein adsorption increases.  This is counter-intuitive, as there is 
decreased surface area for adsorption and increased PEG density on the PEGylated nanogels.  
This can be explained by protein stability; however the more likely cause is the aggregation of 
the nanogels in ionic fluids.  The aggregation, as observed in Figure 4.4 leads to potential 
entrapment of BSA. The surface hydrolysis mediated PEGylation did prevent a significant level 
of protein from adsorbing onto the particles, as the protein binding levels are statistically 
insignificant from no protein adsorption.   
 
The dQCM studies are depicted in Figure 4.16.  These studies show that there is a significant 
amount of protein adsorption on the p(NIPAAm-co-AA) particles, and though some of it does 
wash off, a large portion of it remains on the surface of these particles.  In contrast, particles 
modified with PEG experiences a much smaller frequency shift, signifying less protein 
adsorption.  Furthermore, the frequency shift returns to zero after a short period of time, showing 
no significant protein binding.  The studies at 45ºC in Figure 4.17 show a similar result, with no 
significant binding to the P(NIPAAm-co-AAm) 20% AAm surface hydrolyzed and PEGylated 
sample, while the P(NIPAAm-co-AA) 20% AA sample has significant protein adsorption.   
 
The dQCM studies do differ from the suspension studies, in that the increase in temperature led 
to a smaller adsorption of BSA compared to its 37ºC, at least for the non-surface modified 
sample.  This confirms that the increase in protein adhesion seen in the suspension protein 
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binding studies is due to the aggregation, and not any increase in protein activity or other 
phemnoena.   
4.4 Conclusions 
The use of AA and AAm has been tested as potential routes for incorporation of carboxylic acid 
functional groups.  AAm was proven to have less of an impact on the temperature response at 
relatively high comonomer concentrations than AA, as seen in the temperature response swelling 
curves.  The particles synthesized are spherical and stable in pure DI water. The subsequent 
aggregation in aqueous solutions with physiologically relevant ionic strength is worrying but 
overall a non-problem, as the blood stream will keep the particles well mixed.  However, this 
does prevent an understanding of the full swelling response in high ionic strength conditions.       
 
The surface hydrolysis process was proven to have little to no effect on the structure of the 
nanogels, beyond what was intended.  The particles remain structurally intact and retain the 
LCST and overall response to variations of temperature.  The 15% AAm sample demonstrates a 
better response to the overall localization of the hydrolysis process, however the increased 
hydrolysis observed with the 20% AAm sample has no limiting impact on the temperature 
response as seen by other PEG grafting mechanisms.   
 
The EDC/NHS surface modification mechanism was proven efficient enough to passivate the 
nanogels, even though the EDC/NHS scheme is a relatively inefficient means for PEG 
attachment, yielding only about a 45% attachment.  That being said, the studies to characterize 
protein binding do show that PEG attachment effectively prevents protein adsorption.  This 
shows that these systems should prove effective in an in vivo study to determine bioavailability 
and circulation half-life of this PEGylation scheme.  This mechanism could also be adapted to 
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other neutral yet hydrolysable based systems to provide a noninvasive route for surface 
modification.   
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Figure 4.1: SEM micrographs P(NIPAAm-co-AAm) nanogels. A. 10% AAm. B. 20% AAm. 
Percentages are molar percentages of total monomer concentration in the feed. 
 
 
 
 
 
 
 
 
 
B A 
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Figure 4.2: Equilibrium swelling ratio vs temperature of P(NIPAAm-co-AAm) nanogels 
prepared at different total monomer molar feed percentages. Percentages are molar 
percentages of total monomer concentration in the feed. (N=3) 
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Figure 4.3: Equilibrium swelling ratio vs temperature of P(NIPAAm-co-AA) nanogels prepared 
at different total monomer feed percentages. Percentages are molar percentages of 
total monomer concentration in the feed. (N=3) 
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Figure 4.4: Equilibrium swelling ratio vs temperature of  15% AAm in P(NIPAAm-co-AAm) in 
1x PBS. Percentages are molar percentages of total monomer concentration in the 
feed. 
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Figure 4.5: Zeta potential of P(NIPAAm-co-AAm) nanogels.  Comparing surface charge of 
unmodified, surface hydrolyzed, and PEGylated nanogels.  Percentages are molar 
percentages of the total monomer feed.  (N=3)  
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Figure 4.6: Equilibrium swelling ratio vs temperature of surface hydrolyzed P(NIPAAm-co-
AAm) prepared with 15% and 20% AAm. Percentages are molar percentages of 
total monomer concentration in the feed. (N=3) 
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Figure 4.7: TEM micrgraphs of surface hydrolyzed 20% AAm, P(NIPAAm-co-AAm) nanogels. 
Percentages are molar percentages of total monomer concentration in the feed. 
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Figure 4.8: Equilibrium swelling ratio vs temperature of  Surface Hydrolyzed 20% AAm 
P(NIPAAm-co-AAm) nanogels surface modified with 2000 MW PEG DLS. (N=3) 
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Polymer Type 
Titration Result 
(mol acid/g 
nanogels) 
Expected Result 
(mol acid/g nanogels) 
% of Expected 
P(NIPAAm-co-AAm) 
20% AAm SH 
1.1 x 10
-3 
1.1 x 10
-3 
100 % 
P(NIPAAm-co-AA)    
20% AA 
1.3 x 10
-3 
1.8 x 10
-3 
72 % 
P(NIPAAm-co-AAm) 
20% AAm SH 
4 x 10
-4 
4 x 10
-4 
100 % 
P(NIPAAm-co-AA)    
15% AA 
3 x 10
-4 
1.3 x 10
-3 
24 % 
P(NIPAAm-co-AAm) 
20% AAm SH 
7 x 10
-4 
<1.1 x 10
-3 
NA 
Table 4.2: Concentration of carboxylic acid functional groups in AA and surface hydrolyzed 
AAm PNIPAAm comonomers.  Expected values from feed ratios and assuming a 
70% hydrolysis from surface hydrolysis.   
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Figure 4.9: Titration of P(NIPAAm-co-AAm) 20% AAm surface hydrolyzed. 
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Figure 4.10: Titration of 20%AA P(NIPAAm-co-AA). 
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Figure 4.11: Titration of surface hydrolyzed 15% AAm P(NIPAAm-co-AAm). 
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Figure 4.12: Titration of 15% AA P(NIPAAm-co-AA). 
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Figure 4.13: Titration of Surface Hydrolyzed 20% AAm P(NIPMAAm-co-AAm) surface 
modified with 2000 MW PEG. 
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A 
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Figure 4.14: MTS proliferation assay of P(NIPAAm-co-AAm) and P(NIPAAm-co-AA) nanogels 
with RAW 264.7 macrophages.  N=4. A. 2 hours. B. 24 hours. Percentages are 
molar percentages of total monomer concentration in the feed. (N=4) 
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Figure 4.15: Mass of protein adsorbed to P(NIPAAm-co-AAm) and P(NIPAAm-co-AA) 
nanogels before and after PEGylation.  Percentages are molar percentages of total 
monomer concentration in the feed. (N=3) 
 
 
 
 
 
 
 
-0.2
0.3
0.8
1.3
1.8
2.3
2.8
3.3
3.8
20%Aac 20%Aam 20%AAM
SH PEG
m
g
 B
S
A
/m
g
 p
a
rt
ic
le
s
 
-0.2
0.3
0.8
1.3
1.8
2.3
2.8
3.3
3.8
20% AA 20% AAm 20% AAm
SH PEG
m
g 
B
SA
/m
g 
P
ar
ti
cl
es
 
68 
 
 
 
Figure 4.16: QCM Protein binding study of A.P(NIPAAm-co-AAm) 20% AAm surface 
hydrolyzed and PEGylated and B. P(NIPAAm-co-AA) 20% AA at 45ºC. A solution 
of 10 mg/mL BSA was introduced at the 400 second mark then washed off at the 
1200 second mark.   
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Figure 4P: QCM Protein binding study of A.P(NIPAAm-co-AAm) 20% AAm surface 
hydrolyzed and PEGylated and B. P(NIPAAm-co-AA) 20% AA at 37ºC. A solution 
of 10 mg/mL BSA was introduced at the 400 second mark then washed off at the 
1200 second mark.   
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CHAPTER 5 
 Drug Delivery From PNIPMAAm Homo and Copolymers 
5.1 Background 
The use of NIPMAM as a monomer to prepare physiologically relevant temperature sensitive 
polymers is an attractive premise for two reasons. First, the critical response of PNIPMAAm 
does not begin until the temperature is well above physiological temperature (37ºC).  Secondly, 
the only criticism is the necessity of attaining temperatures that could induce hyperthermia in 
order to actuate drug release[51].  This calls for copolymerization to depress the LCST response 
of NIPMAM based nanogels.  
 
NIPAAm has been copolymerized with a variety of monomers with different traits, including 
hydrophobic, hydrophilic, and ionic traits.  Figure 5.1 shows the general trends for how 
incorporation of different commoners impacts the LCST of PNIPAAm based copolymers.  In 
general the more hydrophobic the copolymer the lower the LCST drops. Conversely, the addition 
of hydrophilic comonomers tends to increase the LCST of PNIPAAm based systems[52].   
 
For example copolymerization with AAc increases the LCST as mol% is increased while the 
addition of butyl methacrylate (BMA) lowers the LCST.  The decline/increase of the LCST 
response with respect to the incorporation of the polymer is a linear trend, with the slope 
dependent primarily on the relative increase of hydrophilicity that the comonomer imparts.  For 
example the inclusion of ionically charged AA imparts a far greater increase in the LCST 
response as compared to AAm. Theoretically, the same should be true for NIPMAAm copolymer 
nanogels.   
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This would be advantageous for the delivery of hydrophobic drugs, as used in chemotherapy, as 
the inclusion of more hydrophobic pockets could improve the inclusion of hydrophobic drugs.    
5.2 Materials and Methods 
5.2.1 Nanogel Synthesis 
NIPMAAm, APS, tert-butyl methacrylate (TBMA), Phenyl Methacrylate (PhMA), ethylene 
glycol phenyl ether acrylate (EGPhA), N-Vinyl Pyrrolidone (NVP), and MBAM, from Sigma 
Aldrich (St Louis, MO); and SDS from Fisher Scientific (Pittsburgh, PA) were all used as 
received. In a standard reaction NIPMAAm, the comonomer, MBAM, and SDS were mixed 
together in 18.2 MΩcm water in the amounts specified in table 5.1 for the 20% comonomer 
nanogels.  This solution was then purged for 30 minutes at 70ºC with Nitrogen under 200 rpm 
stirring with a stir bar in a round bottom flask.  Then APS dissolved in 18.2 MΩcm water was 
injected and the reaction was allowed to progress for 2 hours under constant stirring.  The 
reaction was then terminated by exposure to air.  The resultant suspensions were then dialyzed 
against 18.2MΩcm water for 2 weeks with twice daily water changes.  All comonomer 
percentages reported in this section are molar feed ratios to total monomer, including crosslinker.   
 
Component mol % of total solution % monomer mol feed 
NIPMAM 0.020% 71% 
TBMA or NVP 0.0072% 20% 
MBAM 9.0x10
-5
% 9% 
SDS 1.9x10
-5
% NA 
Water 99.8% NA 
Table 5.1: Molar composition of nanogel synthesis. 
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5.2.2 PARTICLE SIZING 
The effect of temperature on particle size was measured using a Malvern Zetasizer ZS (Malvern, 
UK). The data was collected by dissolving freeze dried particles in 1 mL of DI water and 
adjusting the temperature by 3ºC increments and then allowed to equilibrate for 60 seconds.  
Temperature was ramped 20ºC-59ºC-20ºC to examine the effect of hysteresis on the samples 
particle size.   
5.2.3 LOADING 
5-flurouracil (5-FU) and Fluorescein from Sigma Aldrich (St. Louis, MO) were used as received. 
The loading procedure involves incubating purified and freeze dried particles in 1xPBS with the 
model drug at known concentrations. Samples were diluted with DI water, centrifuged for 10 
minutes at 14,000 rpm in a microcentrifuge to collapse particles out of solution.  The supernatant 
was removed and measured by a BIO TEK Synergy HT plate reader at 350 nm and 290 nm for 
fluorescein and 5-FU respectively. The resultant concentration was subtracted from the initial 
concentration and the difference is determined to be the total amount loaded into the particles.  
At the end of the study a final loading is determined and particles are washed 3 times with 18.2 
MΩcm water and then freeze dried. 
5.2.4 Pyrene Fluorescence 
Pyrene was initially dissolved in acetone at a concentration of 0.2 mg/mL.  10 µL of this solution 
was then dropped into a 96 well plate and the acetone was allowed to evaporate in a fume hood. 
200 µL of particles at a concentration of 0.1 mg/mL was then added to the wells and allowed to 
mix overnight.  These samples were then read in a Biotek Cytation 3 plate reader at an excitation 
wavelength of 336 nm and emission at 373 nm and 383 nm.   
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5.2.5 Partition Coefficient Studies 
DOX in water at a concentration of 1 mg/mL was mixed with an equal volume of particles at a 
concentration of 1 mg/mL both at 37ºC.  This suspension was then held at 37ºC for 2 hours, to 
allow equilibration.  All particles and a control solution were then filtered through a 0.2 µm filter 
to remove particles.  These samples were then measured at a wavelength of 450 nm to determine 
the concentration of drug left after filtration.   
5.2.6 Cytotoxicity 
Particle cytotoxicity was determined using L929 fibroblasts as model cells.  Cells were initially 
grown in Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS) 
with phenol red.  All cells were allowed to be passaged three times before studies were 
performed.  Cells were grown for 24 hours at a seeding density of 2.0 x 10
4
 cells per well.  The 
media was then replaced with phenol red free media containing 2% FBS with particles at varying 
concentrations.  Media containing no particles and a 15% bleach solution were used as controls.  
These solutions were allowed to incubate with particles for 2 and 24 hours and then cytotoxicity 
was measured using and MTS assay.       
5.3 Results and Discussion 
5.3.1 Effect of SDS Concentration 
Figure 5.2 demonstrates the effect of SDS concentration on particle size and batch-to-batch 
variability The increase of the surfactant concentration leads to a linear decrease in the size of the 
particles and a decrease in variability between batches. Below 3E-4 mol % SDS the size levels 
off and is highly reproducible.  This is likely due to a limited effect of variations in the 
SDS:Monomer ratio.   Figure 5.3 examines the impact of the particle size on cytotoxicity; 
however there is no significant cytotoxicity of any PNIPMAAm nanogels.    
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5.3.2 Swelling Response of PNIPMAAm Copolymers 
The temperature dependent swelling results from synthesis of nanogels with different 
comonomers are summarized in Table 5.3.  The graphs of the swelling response of the different 
comonomers as well as their sigmoidal fit (as described by Equation 5.1) are graphed in figures 
5.4-5.13.  The fit of the sigmoidal fit provides a quantitative measurement of the sharpness of the 
temperature response in the form of the value of the exponent (p).   
  
 𝐸𝑆𝑅 =
𝐸𝑆𝑅𝑚𝑎𝑥 − 1
1 + (
𝑇
𝑇𝐿𝐶𝑆𝑇
)𝑃
+ 1 Equation 5.1 
 
The addition of all comonomers has a negative impact on the overall swelling response.  They 
also diminish the sharpness of the response as seen by the fit’s sigmoidal exponent, with the 
exception of 10% TBMA.  However, this is mildly uncertain as the fit is dubious due to the 
invalidation of the first 10 points of the curve for the model fit.  In all instances increasing the 
comonomer decreases the sharpness of the response. 
 
All comonomers decrease the particle size, though the hydrophilic comonomers (AAm and 
EGPhA) increase particle size as the concentration increases while the hydrophobic comonomers 
(TBMA and PhMA) have the inverse effect.  Though there are many factors that could impact 
the particle size, including purity and polymer reaction kinetics, these trends do exist outside of 
the batch-to-batch error observed in Figure 5.2. 
   
The shift of the LCST of PNIPMAAm’s copolymers does not follow the same trend seen for 
PNIPAAm in Figure 5.1. Hydrophilic comonomers seem to decrease the LCST while the 
hydrophobic comonomer, TBMA, raises the LCST slightly, which is the inverse to the trends 
observed with PNIPAAm [53].    The shift in the LCST response due to the inclusion of the 
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hydrophilic comonomers is likely another symptom of the decrease of the sharpness of the 
temperature response.  The elongation of the swelling curve results in the shift of the LCST.  
This is also seen for the other hydrophobic comonomer used, PhMA, which results in the 
greatest shift of the LCST.  As seen in their swelling curves, all of the nanogel systems achieve 
total collapse at or around 50ºC, while their collapse onsets vary from 30ºC-40ºC.  This wide 
range of onsets leads to different midpoints in the line, which causes the shifts observed in the 
LCSTs.     
 
Copolymerizations with TBMA demonstrated flat repeatable swelling responses, as exhibited by 
their small error bars and linear ESR above the LCST.  The 10% TBMA sample in Figure 5.4 
exhibits a linear increase in ESR until its critical onset at 41ºC.  10% TBMA shows one of the 
more drastic collapses between physiological temperature and 47ºC, seeing a 70% change in 
volume in this range.  Increasing the comonomer concentration to 20% TBMA eliminates the 
steady increase, as the swelling remains constant until 41ºC where collapse begins, and collapses 
to about 50% of its initial volume around 47ºC.  The TBMA systems have the highest exponent 
values of the comonomer nanogels, signifying that the addition of these hydrophobic 
comonomers results in the sharpest response to variation of temperature. 
 
Copolymerization with PhMA greatly reduces the onset temperature of the collapse to 30ºC, 
however full collapse still takes until 50ºC, as seen in Figure 5.5 and 5.6.  This could be due to a 
number of factors, but is likely due to variations of the comonomer concentration as the particles 
were formed.  Both PhMA formulations demonstrate a repeatable and reproducible uptick in 
swelling volume around 37ºC before attaining full collapse between 44ºC-50ºC.  These systems 
could prove interesting as drug delivery vehicles, as there is still a significant change in the 
swelling volume between physiological temperature and 47ºC.   
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The copolymerization with NVP shows a similar uptick to that exhibited by the PhMA 
copolymers, however, the large error in the swollen state hides this phenomenon.  The collapse 
starts well before physiological temperature, this combined with the hydrophilic nature of the 
system signifies that these NVP based systems are not suitable for drug delivery.    
 
The EGPhA copolymer nanogels show a much more gradual response, beginning their collapse 
at 30ºC and attaining full collapse at 50ºC.  Increasing the comonomer concentration from 10%-
20% leads to a slight increase in the maximum ESR, but the overall trend remain.  These 
modifications are likely due to the hydrophilic nature of EGPhA, as they increase the 
hydrophilicity of the nanogel and thus the overall swelling volume, but then also limit the ability 
of the system to collapse due to the increased presence of hydrophilic domains.      
 
Similar trends are not seen with AAm as a comonomer, though this can be explained by the fact 
that AAm is less hydrophilic.  The inclusion of AAm greatly reduced the maximum ESR with 
the 20% AAm nanogels exhibiting the smallest ESR of all the nanogels synthesized.  These gels 
also exhibit a broad response of the collapse, as both nanogels begin their collapse around 33ºC 
and reach a steady ESR at 50ºC.     
 
5.3.3 Loading Results 
The loading of particles with model drugs showed an interesting, however predicted, 
phenomena.  As seen in Figure 5.14 the hydrophobic comonomer increases the loading of the 
hydrophobic drugs.  The NVP polymers show no signs of successfully loading the more 
hydrophilic 5-FU.  This result might be indicative of less of a phase separation between the more 
hydrophobic polymer systems and the surrounding water.  Since the loading and entrapment of 
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these drugs in these LCST systems is dependent on phase separation, and improved solubility in 
the polymer phase.   
5.3.4 Pyrene Fluorescence 
Pyrene fluorescence experiments in Figure 5.15 show that, largely, these nanogels do not have a 
hydrophobic makeup that varies significantly from that of water, which makes sense as 
hydrogels are known for being hydrated systems.  The TBMA copolymer systems are the only 
systems to exhibit a change in pyrene fluorescence between 37ºC and 45ºC, while 20% TBMA is 
the only one to significantly vary from water at 37ºC, showing that TBMA is the most 
hydrophobic comonomer used in this study.  These trends are observed, however no system 
demonstrates any large variation from fluorescence in water.        
5.3.5 Partition Coefficient Studies 
All of the systems demonstrate similar partition coefficients with the exception of 20% EGPhA, 
as seen in Figure 5.16.  This is likely due to EGPhA being hydrophilic.  The data also shows that 
increasing the temperature results in a large drop in the partition coefficient, especially TBMA.  
This could be explained by a number of factors, including an increase in DOX’s solubility in 
water and a decrease in volume of the particles, as the partition coefficients are based on dry 
weight of particles. 
 
These studies are slightly surprising, due in large part to the hydrophobic nature of Dox and the 
hydrophobic shift that is experienced across the LCST of these nanoparticles.  However, the 
45ºC is in the middle of the phase transition for most of these systems, and was chosen mainly as 
the highest temperature at which limited exposure demonstrates little hyperthermic ablation in 
tissue (cite).  These results demonstrate a shift in solubility that could likely be used for drug 
delivery.  The 10% TBMA sample, in particular, shows a significant partitioning effect at 37ºC 
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that drops to 0 at 45ºC.  This could be beneficial for drug delivery, as it would encourage entire 
release of the drug payload.   
5.3.6 Cytotoxicity Studies 
Figure 5.17 shows the cytotoxic effect of the copolymer based nanogels.  Again, there is no 
significant toxicity of the nanogels at 6 or 24 hours up to a concentration of 5 mg/mL.  The 
particles do demonstrate an increase in the enzymatic activity of the cells.  The MTS assay used t 
measure the toxicity of the nanoparticles depends on the presence of nicotinamide adenine 
dinucleotide (NADH).  This molecule is produced from the activity of dehydrogenases necessary 
for cell proliferation.  This increase could be due to either an experimental anomaly or it could be 
stress induced due to the presence of the nanoparticles.  
5.4 Conclusions     
PNIPMAAm copolymers can be synthesized with a range of different copolymer types.  The 
analysis of the swelling response shows that the hydrophobicity of the comonomer does not have 
the same impact as that observed on PNIPAAm based copolymers.  No copolymer system 
demonstrated a significant increase in LCST and the only decrease observed occurred largely 
due to in inhomogeneities in the swelling response.   
 
Further, analysis of these systems for hydrophobicity showed that no systems are significally 
more hydrophobic than water, likely due to the hydrated nature of the polymers.  This result is 
surprising as the partition coefficient studies demonstrated high partitioning of DOX into the 
hydrogels.  These studies also revealed a preference for systems containing hydrophobic 
comonomers, such as TBMA and PhMA over their hydrophilic counterpart, EGPhA. These 
results were even the trend for more hydrophilic model drugs such as 5-FU.  The hydrophilic 
comonomers demonstrated that even though the Pyrene studies revealed similar hydrophobicity, 
the drug had no preferential loading for these systems. 
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Studying the effect of temperature on these systems revealed that these systems exhibt a decrease 
in partitioning that cannot be explained by their swelling response.  The trend reveals nothing 
about the amount of comonomer’s effect on the partitioning.  These studies do show that the 
release of the drug is due to a decrease of the partitioning, though could be mildly related to the 
collapse and drop in overall volume of the nanoparticles.    
 
These studies even went on to prove that these particles have no cytotoxic effect even at 
relatively high concentrations of 5 mg/mL, regardless of comonomer.  Overall these studies 
demonstrate that comonomer can affect the impact of these systems as drug delivery vehicles.  
The higher the hydrophobicity of the comonomer, as demonstrated by TBMA, the better the 
swelling response and drug compatibility of the system.  However, increasing the comonomer 
concentration to higher levels can start to diminish the temperature sensitivity of these nanogels, 
as pure PNIPMAAm demonstrated a sharper temperature response than its copolymerized 
counterparts.      
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Figure 5.1: Effect of comonomer concentration and type on the LCST of PNIPAAm based 
hydrogels [53].   
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Name 5-Fluorocuracil Fluorescein Doxorubicin HCL 
Structure 
 
 
 
Molecular 
Weight 
130.08 g/mol 332.31 g/mol 579.88 g/mol 
λ of 
absorbance 
290 nm 350 nm 450 nm 
Water 
Solubility 
12.2 mg/mL insoluble 10 mg/mL 
Table 5.2: Model drug information.[54, 55] Chemical BOOK 
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Figure 5.2: Effect of SDS concentration of total mols on the size and batch-to-batch variability of 
PNIPMAm nanogels at 25ºC. (N=3) 
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Figure 5.3: Cytotoxicity of PNIPMAAm nanogels of varying particle size. MTS Assay of L929 
fibroblasts at A. 6 hours. B. 24 hours. n=4.  Positive control 2% FBS in Dulbecco’s 
Modified Eagle Medium. 
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Comonomer 
Concentration 
Zavg 
diameter 
25ºC (nm) 
PDI LCST(ºC) 
Overall Volume 
Swelling 
Response 
Power 
Exponent 
R
2
 Value 
of Fit 
NIPMAAm 615.8 0.073 45 11.5 19.14 0.681 
10% TBMA 366.45 0.172 46 5.68 61.4 0.998 
20% TBMA 309.5 0.118 46 5.78 18.7 0.963 
10% PhMA 427.8 0.299 33 8.93 11.6 0.962 
20% PhMA 341.5 0.316 44 4.43 8.95 0.323 
10% EGPhA 242.1 0.022 41 2.89 9.80 0.861 
20% EGPhA 272.5 0.002 42 3.80 8.63 0.806 
10% AAm 478.6 0.019 41 4.01 11.94 0.939 
20% AAm 716.8 0.187 38 2.23 7.86 0.738 
20% NVP 666.9 0.156 41 9.0 8.29 0.656 
 
Table 5.3: Characteristics of swelling curves of PNIMAAm copolymer nanogels.  Percentages 
are percentages of total monomer concentration in the feed. 
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Figure 5.4: Equilibrium swelling ratio vs temperature of PNIPMAAm nanogels. 
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Figure 5.5: Equilibrium swelling response vs temperature of P(NIPMAAm-co-TBMA) 10% 
TBMA nanogels. (N=3) 
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Figure 5.6: Equilibrium swelling ratio vs temperature of P( NIMAAm-co-TBMA) 20% TBMA 
nanogels. (N=3) 
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Figure 5.7: Equilibrium swelling ratio vs temperature of  P(NIPMAAm-co-PhMA) 10% PhMA 
nanogels. 
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Figure 5.8: Equilibrium swelling ratio vs temperature of P(NIPMAAm-co-PhMA) 20% PhMA 
nanogels. (N=3) 
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Figure 5.9: Equilibrium swelling ratio vs temperature of P(NIPMAAm-co-EGPhA) 10% EGPhA 
nanogels. (N=3) 
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Figure 5.10: Equilibrium swelling ratio vs temperature of P(NIPMAAm-co-EGPhA) 20% 
EGPhA nanogels. (N=3) 
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Figure 5.11: Equilibrium swelling ratio vs temperature of  (NIPMAAm-co-AAm) 10% AAm 
nanogels. (N=3) 
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Figure 5.12: Equilibrium swelling ratio vs temperature of  P(NIPMAAm-co-AAm) 20% AAm 
nanogels. (N=3) 
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Figure 5.13: Equilibrium swelling ratio vs temperature of P(NIPMAAm-co-NVP) 20% NVP 
nanogels. (N=3) 
 
 
 
 
 
 
  
1
3
5
7
9
11
13
15
17
20 25 30 35 40 45 50 55 60 65
ES
R
 
Temperature (ºC) 
95 
 
 
 
Figure 5.14: Loading of model chemotherapeutics into PNIPMAAm based copolymers.  
Percentages represent percent of total monomer in the feed solution. (N=3) 
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Figure 5.15: Pyrene fluorescence ratios of PNIPMAAm based copolymers at 37ºC. (N=3) 
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Figure 5.16: Dox nanoparticle partition coefficient studies at 37ºC and 45ºC.  (N=3) 
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Figure 5.17: The effect of comonomer. MTS Assay of L929 fibroblasts at A. 6 hours. B. 24 
hours. n=4. Positive control 2% FBS in DMEM. Negative control DI Water. 
Percentages are molar percentages of total monomer concentration in the feed. 
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CHAPTER 6 
 Core/Shell Hydrogels for Improved Retention of Chemotherapeutics 
6.1 Background  
The development of temperature responsive systems has focused on the loading and release from 
the hydrated polymer mesh.  This is abnormal, as hydrogel systems used for drug delivery 
depend on a collapsed mesh that restricts diffusion of the payload by decreasing the mesh size.  
Because of the small molecular weight of chemotherapeutics and the hydrated nanogels used to 
deliver them, the loading and release is based primarily on diffusive limitations and partitioning 
between the nanogel and the surrounding aqueous solution.  Many of these LCST systems have a 
noticeable release, even at temperatures well below their critical point[56]. This release is 
observed in the work of Gran (Figure 6.1) with P(NIPAAm-co-AA) based copolymers [57].  
 
Since the relative concentration of drug in the polymer is linked to the solubility of water, there 
can be a ceiling to the loading limit.  However, these systems can still prove effective during the 
in vitro and in vivo test trials due to the slow mass transfer associated with diffusion and the 
relatively short time it takes particles to accumulate in tumors[5].   
 
The slow diffusional release  time scale allows for limited release as the particles accumulate, 
than the convective release that is experienced after triggering. However, results, as those 
depicted in Figure 6.1, are skewed due the schemes developed to test the loading and release of 
these particles.  Because these systems are tested in closed environments, the seemingly 
asymptotic nature of the curve is an artifact of simple mass transfer limitations.  So, in vivo, the 
only limitation to release is the long timescale associated with diffusion.  As the relative 
equilibrium is achieved between the two volumes the rate of release decreases.  However, unlike 
this closed environment, in the body the released drug is continuously metabolized, and taken up 
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by the cells and tissue in the body. This means that equilibrium is never achieved, and there is 
always a significant concentration gradient driving release. 
 
There are two approaches to preventing the premature release of the drug payload.  One method 
of addressing this problem is to conjugate the drug to the backbone of the polymer via using a 
physical linker, thus creating the so-called “pendant systems”. However, drug release is now 
affected by the ability to hydrolytically free the incorporated drug, reproducibly and always at 
the same site so that what is released is the drug itself and not drug derivatives.  There have been 
a number of systems that have pursued these covalently linked systems for preventing the release 
of their drug payloads[25].        
 
Another method to limit this release while increasing loading capacity is to adjust the chemical 
potential of the drug in the polymer.  This entails development of hydrogels that will allow high 
solubility of the drug in the matrix. This approach has two potential pitfalls. The first is 
implementation, since LCST hydrogels depend on a hydrated state at physiological conditions, 
including large amounts of a hydrophobic moiety could limit the temperature response.  The 
second issue is that increasing the partition coefficient of the hydrogel would also limit the 
eventual release due to the high solubility in the hydrogel and limited solubility in physiological 
fluid.  Core/Shell systems could provide a solution to both of these limitations, while still 
providing for increased drug retention.  First, separating out the hydrophobic moiety into a shell 
material will limit the impact on the temperature response. In order to ensure a high release level, 
these systems will depend on a phenomenon observed when combining thermoresponsive 
nanogels with superparmagnetic iron oxide nanoparticles (SPIONS). Figure 6.2 shows release of 
BSA in response of a number of different stimuli.  When this system is intensely heated in the 
presence of SPIONS it results in a burst release [59].  
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This mechanism could prove useful in emitting the entire drug payload of these core/shell 
systems, overcoming any limitations due to the increased partitioning of the drug payload.          
6.2 Materials and Methods 
6.2.1 Core Synthesis 
NIPMAM, APS, and MBAM were obtained from Sigma (St. Louis, MO); and SDS from Fisher 
Scientific (Pittsburgh, PA) were all used as received. In a standard reaction, NIPMAM, MBAM, 
and SDS are mixed together in 18.2 MΩcm water in the amounts specified in the table below.  
This solution was purged for 30 minutes at 70ºC with Nitrogen under 200 rpm stirring with a 
football shaped stir bar in a round bottom flask.  Then APS, dissolved in 18.2 MΩcm water was 
injected and the reaction was allowed to progress for 2 hours under constant stirring.  The 
reaction was then terminated by exposure to air.  Nanogels not intended to be used in shell 
development were then purified against 18.2 MΩcm water for two weeks with twice daily water 
changes and is then freeze dried.   
 
Component mol % of total solution % of total monoer mol feed 
NIPMAM 0.024% 95% 
MBAM 5.0x10
-5
% 5% 
SDS 1.9x10
-5
% NA 
Water 99.8% NA 
Table 6.1: Molar composition of core synthesis. 
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6.2.2 Shell Development 
After 6 hours a solution of the comonomer MBAM, and APS was injected into the core synthesis 
reaction.  The amount of shell comonomer added was 50%  by mol of NIPMAAm used in the 
core synthesis.     
 
Component mol Percent % monomer mol feed 
TBMA, EGPhA, PhMA 0.024% 95% 
MBAM 5.0x10
-5
% 5% 
Water 99.8% NA 
Table 6.2: Molar composition of shell synthesis. 
6.2.3 Particle Sizing  
The effect of temperature on particle size was measured using a Malvern Zetasizer ZS (Malvern, 
UK). The data were collected by dissolving freeze dried particles in 1 mL of DI water and 
adjusting the temperature by 3ºC increments and then allowed to equilibrate for 60 seconds.  
Temperature was ramped 20ºC to 59ºC and then down to 20ºC to examine the effect of hysteresis 
on the samples particle size.   
6.2.4 DSC Studies 
Modulated DSC studies were performed with a  DSC (Q2000, TA instruments, New Castle, DE).  
Samples were loaded at a minimum weight of 5 mg into aluminum pans and sealed.  Studies 
were run from 20-200ºC in a nitrogen environment. 
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6.2.5 NMR Studies 
Nuclear magnetic resonance spectra were taken with a NMSR spectrophotometer (model 400 
MHZ, Varian Palo Alto, CA) with a Direct Drive sample changer.  Samples were dissolved in 
deuterated acetone at a concentration of 20 mg/mL. 
6.2.6Pyrene Fluorescence 
Pyrene was initially dissolved in acetone at a concentration of 0.2 mg/mL.  A sample of 10 µL of 
this solution was then dropped into a 96 well plate and the acetone was allowed to evaporate in a 
fume hood. A sample of 200 µL of particles at a concentration of 0.1 mg/mL was then added to 
the wells and allowed to mix overnight.  These samples were then read in a Biotek Cytation 3 
plate reader (Bio Tek, Winooski, VT) at excitation wavelengths 333 nm and 338 nm and 
emission at 390 nm.   
6.2.7 Fluorescein Loading Studies 
Fluorescein loading was achieved by mixing particles and fluorescein at a concentration of 1 
mg/mL, each; in a 9:1 water:DMSO solution.  The particles were then separated from unloaded 
fluorescein by centrifugal filters.  The loading levels were determined by measuring the 
concentration of fluorescein in the filtrate.  This value was then subtracted from the initial 
concentration of fluorescein.  
6.2.8 DOX Loading Studies 
Loading studies were performed by dissolving particles and drug in a 50:50 DMSO:Water 
solution.  The particles and drug were dissolved at concentrations of 5 mg/mL each.  These 
solutions were then dialyzed against 18.2 MΩcm water until the dialysate was clear.  These 
suspensions were then freeze dried for release studies. 
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6.2.9 Temperature Release Studies 
Release studies were performed by preparing solutions of drug loaded particles suspended in a 
37°C 1 X PBS solution at a concentration of 0.5 mg/mL.  It was incubated for 6 hours taking 
intermittent time points.  After 6 hours the temperature was then increased to 45°C and the 
incubation was allowed to proceed for another 2 hours taking more time points.  
6.2.10 Magnetic Nanoparticle Incorporation 
N-hydroxy succinimide ester coated magnetic nanoparticles (Sigma Aldrich, St Louis, MO) were 
purchased from Sigma Aldrich (St Louis, MO).  These nanoparticles were then coated with vinyl 
groups by reacting with 2-amino ethyl methacrylate in borate buffer pH 8.4.  These particles 
were then reacted in a standard core synthesis reaction described previously in section 6.1. The 
particles were first suspended in methanol and then this solution was mixed with a solution 
prepared from Table 6.1.  These samples were then heated in a sonication bath at 70°C.  After 
heating, an APS solution was then injected into the reaction to initiate the reaction, and the 
reaction was allowed to proceed for 2 hours.   
6.2.11 TEM Images 
Images were obtained on an Transmission Electron Microscope (FEI Tecnai, Hillsboro, OR)  
operating at 80 kV. Carbon coated copper grids (400 mesh) were plasma treated using an 
Emitech Glow Discharge instrument to render them hydrophilic prior to adding 5 µL of the 
nanoparticle suspension. After 30 seconds, the nanoparticle suspension was wicked off using 
Whatman 1 filter paper. The particles were negatively stained by placing a 5 µL drop of 2% 
phosophotungstic acid, pH 8.0, on the particle-coated grid for 30 seconds before being wicked 
off with Whatman 1 filter paper. 
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6.2.12 AMF Release Studies 
Magnetic nanoparticle incorporated nanogels were loaded as described in the DOX Loading 
Studies section.  These nanocomposites were then incubated at 37°C for 6 hours, and overall 
release was measured at the end of the 6 hours.  The particles were then heated with an RDO.      
6.3 Results and Discussion 
6.3.1 DLS Swelling Responses 
The results obtained here indicate that the swelling response of PNIPMAAm is relatively 
unaffected by the addition of the various shell comonomers.  The graphs of the temperature 
response of PNIPMAAm/PTBMA, PNIPMAAm/EGPhA, and PNIPMAAm/PhMA core/shell 
systems are in Figure 6.4, 6.5, and 6.6 respectively. By fitting these swelling results to Equation 
6A, we can quantify the sharpness of the responses of these systems by determination of the 
exponent p.  These values can be found in Table 6.3, along with other characteristics of the 
system’s swelling response.  
  
 𝐸𝑆𝑅 =
𝐸𝑆𝑅𝑚𝑎𝑥 − 1
1 + (
𝑇
𝑇𝐿𝐶𝑆𝑇
)𝑃
+ 1 Equation 6A 
 
All core/shell systems altered the swelling response significantly.  The large decrease in overall 
swelling response is due to the encapsulation of the PNIPMAAm core in a non-thermoresponsive 
shell.  Because the shell does not collapse, its volume remains constant Even though the core still 
undergoes collapse, the overall volume does not change as drastically due to the constant shell 
thickness.    
 
None of the systems have a large change in the LCST, with the largest shift in its critical 
temperature occurring with the PNIPMAAm/PTBMA core/shell system, down to 43ºC.  
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However, all of the systems remain swollen until 37ºC before syneresis begins and the full 
response is observed by 50ºC.  This temperature response is essential for their application.   
 
The PNIPMAAm/PTBMA core shell nanogels demonstrates a consistent volume swelling ratio 
up to 37ºC and a fairly sharp response with a sigmoidal exponent of 9.8.  This is still half as 
sharp as the collapse of PNIPMAAm nanogels, though a large portion of its collapse is still 
achieved by 45ºC.   
 
PNIPMAAm/PEGPhA core/shell nanogels exhibit the sharpest response of the core/shell 
materials.  However, there is large variability of these systems in their swollen states.  This is due 
to the hydrophilic polymers not being ideal for the emulsion based synthesis of these systems 
and the likelihood of a highly branched particle leading to large variation of hydrodynamic radii.  
However, the sharp collapse between 37ºC and 47ºC make it a viable option for drug delivery 
purposes.   
 
The PNIPMAAm:PPhMA core/shell system demonstrates a response similar to that of the 
PNIPMAAm:PTBMA core/shell system due to the similarities of hydrophobicity.  However, the 
PNIPMAAm/PPhMA nanogels experience a greater change in their overall swelling ratio.           
6.3.2 Core/Shell Characterization 
The NMR graphs for the different systems are seen in Figure 6.7-6.10.  Figure 6.7 demonstrates 
the groups expected with a PNIPAAm nanogels.  The chacteristic peak of the polymer backbone 
is seen at the 2.9 shift.  The characteristic PNIMAAm shifts at the peaks of shifts 3.9 and 1.1.  
The shift at 1.1 corresponds to the isopropyl and vinyl methyl groups, while the shift at 3.9 
corresponds to the tertiary carbon’s lone proton.  The shift at 3.9 is the important shift to identify, 
as it is unique to the structure of NIPMAAm. NMR measurements of crosslinked nanoparticles 
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are often not preferred due to the fact that fluid NMR only detects groups dissolved in water.  
This fact aids the confirmation of core/shell structure as solution NMR only detects the groups 
near the surface of a crosslinked nanoparticle.      
 
Figure 6.8 shows the characteristic NMR of the PNIPMAAm/PTBMA core/shell system.  This 
NMR structure shares many of the same shifts as the PNIPMAAm NMR spectra, such as the 
polymer backbone peak at 2.9 and the shift for methyl groups at 1.1.  However, due to the lack of 
a peak at the 3.9 shift it can be concluded that the NMR of these samples did not detect the 
presence of NIPMAAm units. 
 
Figure 6.9 shows the NMR of the EGPhA system, and again there is the lack of the characteristic 
NIPMAAm peak at the 3.9 shift.  In its place are the shifts for EGPhA’s ethyl groups.  EGPhA’s 
phenyl group shifts are seen at the 6.9 and 7.2 shifts and we see the characteristic backbone peak 
at the 2.9 shift.   
 
The core/shell synthesis of PNIPMAAm/PhMA’s NMR spectra is seen in figure 6.10.  Unlike 
it’s counterparts there are characteristic peaks of PPhMA and PNIPMAAAm.  The phenyl group 
shifts at 7.2 and 7.4 as well as the isopropyl’s tertiary carbon’s hydrogen shift at 3.9.  This result 
means that there is either not a strict separation between the core and shell domains or that 
PhMA was not able to fully coat the particle at these molar ratios.   
 
DSC was also used to characterize the different domains of the core/shell systems, as seen in 
Figures 6.11-6.14.  The uncoated PNIPMAAm based hydrogel’s thermogram is seen in 6K and 
shows two glass transition temperatures (Tg), one at 75ºC and one at 110 ºC.  The reported value 
for PNIPMAAm’s Tg is 110ºC, meaning the Tg detected at 75ºC is due to the presence of a 
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plasticization agent, such as water or unpurified surfactant.  Regardless, this result provides the 
baseline for characterization of the Core/Shell structures. 
 
Figure 6.12 is the thermogram of the PNIPMAAm/PTBMA core/shell structures.  This figure 
shows similar results to the thermogram PNIPMAAm nanogels, but this is largely due to the fact 
that PTBMA and PNIPMAAm have identical glass transition temperatures of 110ºC.  The 
thermogram of the PNIPMAAm/PEGPhA nanogels demonstrates the separate Tgs indicative of 
multiple domains, with phase transitions at 90ºC, 127ºC and 190 ºC.  There is a slight increase in 
the Tgs of the PNIPMAAm domains, likely due to domains of copolymers of P(NIPMAAm-co-
EGPhA).   
 
 Figure 6.14 is the DSC thermogram of the PNIPMAAm:PPhMA core/shell system.  This 
thermogram shows only one Tg at 127°C, again signifying potential copolymerization of 
PNIPMAAm with its shell comonomer.   
6.3.4 Pyrene Fluorescence 
The pyrene fluorescence in Figure 6.15 shows no significant impact on the hydrophobicity of 
this system.  Meaning that the systems are still hydrated and have similar hydrophilic states to 
that of water, which is not surprising due to the hydrated nature of these nanogels. 
6.3.5 Fluorescein Loading and Release 
The loading of fluorescein into core/shell nanogels shows no significant improvement over their 
unmodified counterpart, as seen in Figure 6.16.  The release in Figure 6.17 does show a 
significant impact on the release of the hydrophobic model.  While the unmodified and 
PNIPMAAm/PEGPhA systems release their payload instantaneously and without stimulus, the 
PNIPMAAm/TBMA core/shell system demonstrates no release over the 6 hour period.  At which 
point release is triggered and a significant release level is attained.   
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6.3.6 DOX-Nanogel Interactions  
The partition coefficient studies in Figure 6.18 show a preference for the PNIPMAAm/PTBMA 
core/shell nanogels.  The partition coefficient is almost double that of PNIPMAAm and 
PNIPMAAm/PPhMA core/shell systems.  This is further visualized by the image of DOX loaded 
nanogels seen in Figure 6.19.  In this image there is an increasing reddish color between 
PNIPMAAm and PNIPMAAm/PPhMA, and PNIPMAAm/PPhMA and PNIPMAAm/PTBMA 
systems. Although this is a qualitative method, this does help to identify that the 
PNIPMAAm/PTBMA system achieved a higher loading level than the other systems.   
 
The DSC thermogram of DOX loaded PNIPMAAm/PTBMA core/shell nanogels is seen in 
Figure 6.20 shows the physical state of the materials.  There is no characteristic crystalline 
melting curve that would indicate that the DOX is in a crystalline state. This shows that the DOX 
loaded in the particles are in an amorphous state, and altering the Tg of the system. The DSC 
thermogram of PNIPMAAm/PPhMA core/shell nanogels is seen in Figure 6.21.  Again, the 
DOX does not impart a crystalline melting curve, however this system’s Tg remains unaltered.  
This is likely due to the lower loading levels with PNIPMAAm/PPhMA core/shell nanogels.     
          
The release profiles for PNIPMAAm/PTBMA and PNIPMAAm/PPhMA core/shell nanogels can 
be seen in Figures 6.22 and 6.23.  Figure 6.22 shows a minimal release for the 
PNIPMAAm/PTBMA core/shell system at 37 ºC over a 6 hour period.  The temperature 
response is then triggered in a water bath and an overall release of 8 µg DOX/mg of particles is 
achieved.   
 
Similarly, the PNIPAAm/PPhMA system in Figure 6.23 shows zero release during the 6 hour 
period at 37ºC, and then the temperature trigger causes the release of the DOX payload, 
delivering 3.7 µg/mg.  These results show that although the system incorporating TBMA had a 
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higher partitioning coefficient and could attain higher loading levels, it has little impact on the 
final delivery levels. The increased partition coefficient limits the release level due to the 
preference of the drug for the hydrogel system over the surrounding solution.   
6.3.7 Iron Oxide Nanopartice Incorporation 
Iron oxide nanoparticles coated in PNIPMAAm/PTBMA can be visualized with TEM, as seen in 
figure 6.24.  These micrographs show that most nanocomposites contain 5 or more iron oxide 
nanoparticles.  These particles have spherical morphology, and a thin shell of polymer, likely due 
to the dry state of the images taken.  The temperature swelling response can be seen in Figure 
6.25.  The swelling responses of these materials are similar to the swelling response of the 
PNIPMAAm/PTBMA core/shell nanogels whose response is in Figure 6.4.   
6.4 Conclusions 
Core/Shell nanoparticles were synthesized and characterized by a number of techniques.  The 
DLS swelling studies demonstrate a lower yet still discernible LCST response of the core/shell 
materials.  The NMR and DSC results confirmed the core/shell structure of the 
PNIPMAAm/PTBMA and PNIPMAAm/PEGPhA core shell systems. However, the 
PNIPMAAm/PPhMA system does not demonstrate the same domain separation, exhibiting only 
one Tg and NMR peaks of both the core and shell material.  This compounded with the 
partitioning results show that the PNIPMAAm/PPhMA synthesis route does not have the same 
effect as copolymerization with TBMA and EGPhA.     
 
Core/Shell nanogels were characterized for their effectiveness as chemotherapeutic delivery 
vehicles.  The inclusion of drug into nanogels is improved by the development of the core/shell 
materials, and the core/shell systems do prevent premature release of their drug payload.  
However, these systems demonstrate relatively low release levels in response to the gentle 
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heating from changes in environment temperature.  Though these release levels are likely limited 
due closed system used to measure this.          
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Figure 6.1: Measurement of release of a model therapeutic, fluorescein, from nanogels at 37 °C 
over a 48 h period. Release is quantified as a percentage of total amount of 
fluorescein loaded in the particles [58]. 
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Figure 6.2: Release profiles from Pluronic F68-iron oxide nanocomposites as a function of time 
for various heating methods [59].  
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Illustration 6.1: Schematic for core shell systems.   
  
Drug loaded shell 
NIPMAAm core 
Iron oxide nanoparticle 
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Polymer 
Z avg 
diameter 
25ºC (nm) 
PDI LCST(ºC) 
Overall 
Volume 
Swelling 
Response 
Power 
Exponent 
R
2
 
Value 
of Fit 
PNIPMAAm 615.8 0.073 45 11.5 19.14 0.681 
PNIPMAAm/PTBMA 351.9 0.231 43 0.82 9.8 0.821 
PNIPMAAm/PEGPhA 222.5 0.36 44 1.4 10.0 0.465 
PNIPMAAm/PPHMA 726.9 0.377 43 1.88 7.7 0.798 
Table 6.3: Characteristics of the swelling responses of core/shell systems with 2:1 molar ratios of 
NIPMAAm:shell monomer in the feed ratio.     
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Figure 6.3: Equilibrium swelling ratio vs temperature of PNIPMAAm nanogels. 5% by mol 
MBAM in the feed. (N=3) 
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Figure 6.4: Equilibrium swelling ratio vs temperature of PNIPMAAm/PTBMA core/shell 
nanogels. 2:1 NIPMAAm:TBMA molar ratio.  5% by mol MBAM in the feed. 
(N=3) 
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Figure 6.5: Equilibrium swelling ratio vs temperature of PNIPMAAm/EGPhA core/shell 
nanogels. 2:1 NIPMAAm:EGPhA molar ratio.  5% by mol MBAM. (N=3) 
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Figure 6.6: Equilibrium swelling ratio vs temperature of PNIPMAAm/PPhMA core/shell 
nanogels. 2:1 NIPMAAm:PhMA molar ratio.  5% by mol MBAM. (N=3) 
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Figure 6.7: H
1
 NMR of PNIPMAAm nanogels.  
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Figure 6.8: H
1
 NMR of PNIPMAAm/PTBMA core/shell nanogels. 2:1 NIPMAAm:TBMA molar 
feed ratio. 5% MBAM. 
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Figure 6.9: H
1
 NMR of PNIPMAAm/PEGPhA core/shell nanogels. 2:1 NIPMAAm:EGPhA 
molar feed ratio. 5% MBAM. 
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Figure 6.10: H
1
 NMR of PNIPMAAm/PhMA core/shell nanogels. 2:1 NIPMAAm:PhA molar 
feed ratio. 5% MBAM. 
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Figure 6.11: DSC thermogram of PNIPMAAm nanogels.5% MBAM. 
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Figure 6.12: DSC Thermogram of PNIPMAAm/PTBMA core/shell nanogels. 2:1 
NIPMAAm:TBMA molar feed ratio. 5% MBAM. 
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Figure 6.13: DSC Thermogram of PNIPMAAm/PEGPhA core/shell nanogels. 2:1 
NIPMAAm:EGPhA molar feed ratio. 5% MBAM. 
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Figure 6.14: DSC Thermogram of PNIPMAAm/PPhMA core/shell nanogels. 2:1 
NIPMAAm:PhMA molar feed ratio. 5% MBAM. 
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Figure 6.15: Pyrene fluorescence studies of PNIPMAAm core/shell nanogels.  2:1 molar ratios of 
PNIPMAAm: shell comonomer. 5% MBAM. (N=3) 
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Figure 6.16: Fluorescein loading of PNIPMAAm core/shell nanogels. 2:1 molar ratios of 
PNIPMAAm: shell comonomer. 5% MBAM.  (n=3) 
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A.  
 
B.
 
Figure 6.17: Fluorescein release from PNIPMAAm core/shell nanogels. 2:1 molar ratios of 
PNIPMAAm: shell comonomer. 5% MBAM. (1 mg/mL particles in DI water)  This 
caption id not clear. 
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Figure 6.18: DOX partition coefficient of PNIPMAAm core/shell nanogels. 2:1 molar ratios of 
PNIPMAAm: shell comonomer. 5% MBAM.  (N=3) 
0
100
200
300
400
500
600
700
800
900
NIPMAAm PHMA TBMA
132 
 
 
 
Figure 6.19: Images of freeze dried DOX loaded PNIPMAAm core shell nanogels. 2:1 molar 
ratios of PNIPMAAm: shell comonomer. 5% MBAM. A. PNIPMAAm. B. 
PNIPMAAm:PPhMA core:shell. C:PNIPMAAm:PTBMA core:shell nanogels. 
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Figure 6.20: DSC Thermogram of PNIPMAAm:PTBMA core/shell nanogels loaded with DOX. 
2:1 NIPAAm:TBMA monomer molar ratio.  
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 Figure 6.21: DSC Thermogram of PNIPMAAm:PPhMA core/shell nanogels loaded with DOX. 
2:1 NIPAAm:TBMA monomer molar ratio.  
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Figure 6.22: DOX release from PNIPMAAm/PTBMA core/shell nanogels. 2:1 molar ratio of 
PNIPMAAm:TBMA.  37ºC for 6 hours, then release triggered in a water bath at 
45ºC.   (N=3) 
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Figure 6.23: DOX release from PNIPMAAm/PPhMA core/shell nanogels. 2:1 molar ratio of 
PNIPMAAm:TPhMA.  37ºC for 6 hours, then release triggered in a water bath at 
45ºC.    (N=3) 
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Figure 6.24: TEM micrograph of 30 nm iron oxide nanoparticles PNIPMAAm/PTBMA 
core/shell 2:1 molar ratio.  
  
138 
 
 
 
Figure 6.25: Equilibrium swelling ratio versus temperature for 30 nm Iron Oxide nanoparticles 
encapsulated in PNIPMAAm/PTBMA 2:1 core/shell systems.  
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CHAPTER 7 
 Schizophrenic Block Copolymers for the Synthesis of Complex Core/Shell 
Theranostic Composites 
7.1 Background 
As discussed previously in chapter 6, a new style of drug delivery systems is necessary in order 
to utilize deswelling nanogels.  The development of these complex systems requires new 
applications of recently discovered chemistries. There has been a big push in recent years to use 
the self-assembly and post-synthesis crosslinking of amphiphilic particles to form these 
core/shell hydrogel systems [40, 58, 59].   These systems are desirable due to the increased 
control over size and polymerization, limiting large discrepancies in polymer molecular weight 
and particle size.  The incorporation of cross-links, however, is still a statistical problem, as the 
cross-linking comonomers are still included randomly throughout the blocks.   
 
The standard reaction schemes for the development of these block copolymers include reversible 
addition-fragmentation chain-transfer (RAFT) and atom-transfer radical-polymerization (ATRP).  
These are two types of controlled polymerizations that limit the concentration of growing 
polymer by including an intermediate ligand that reversibly reacts with free radicals[60].  
However, these are polymerization mechanisms that depend on low oxygen concentrations and 
high levels of other dangerous chemicals.  New forms of ATRP polymerizations offer avenues 
around these issues. Initiators for continuous activator regeneration (ICAR) and activators 
regenerated by electron transfer (ARGET) ATRP systems include mechanisms to regenerate the 
copper catalysts that are necessary for ATRP reactions, allowing for higher oxygen content and 
less pure monomers [61].   
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ARGET ATRP has been shown to work with a number of monomers including NIPAAm, 
making it a promising candidate for a synthesis mechanism of these particles.  ARGET ATRP 
works as shown in illustration 7.1.  Essentially, the reaction is initiated when the reduced 
copper/ligand complex reduces the initiator to start the reaction.  This reaction is in equilibrium, 
favoring the deactivated state. Normally, in ATRP reactions, oxygen acts as a free radical 
scavenger terminating the reaction and oxidizing the copper.  ARGET overcomes this by 
charging the solution with a reducing agent to regenerate the reduced copper catalyst[60].   
 
This methodology has been shown to work with NIPAAm and functionalized methacrylate based 
systems, and provides an easy mechanism for the attachment of PEG via a macroinitiator[62].  
There has also been great success including monomers that provide a variety of cross linking 
strategies.  These strategies are outlined in Table 7.1.  With these mechanisms and the relatively 
robust nature of ARGET ATRP reactions, compared to other controlled polymerizations, 
amphiphilic block copolymers can be easily synthesized for self-assembled covalently cross 
linked micelles, imparting all of the factors necessary for an effective delivery method.      
 
Much as in chapter 6, these methods will be used to develop hydrophobic shell/temperature 
responsive core system.  The system is visualized in illustration 7.2, where, by using a PEG 
corona and the hydrophobic collapse of PNIPMAm gels, systems can be synthesized like those 
in image 7B with a hydrophobic middle section.   Cross-linking comonomers can be 
incorporated into both the core and shell systems, and the micelles can be cross-linked to form 
nanogels. 
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7.2 Materials and Methods 
7.2.1Block co-polymer synthesis 
Block copolymers were synthesized using an ARGET ATRP reaction scheme.  The first step 
involved dissolving a PEG macroinitiator (PEG ethyl isobutyrate) with ligand (tris pyridyl 
methyl amine (TPMA), Copper (II) Bromide, TBMA, and glycidyl methacrylate (GMA) in 35 
mL ofwater in the values seen in Table 7.2.  This reaction was then purged with nitrogen and a 
solution of the reducing agent, ascorbic acid (ASC), in water was injected.  This solution was 
then allowed to react for 2 hours, at which point a solution of 0.008 mol of NIPMAAm and 0.4 
mol of GMA in 20 mL of water was nitrogen purged and transferred into the reaction to form the 
final block.  These solutions were then dialyzed against 18.2MΩ cm water for 1 week with twice 
daily water changes. 
 
Component Mol 
Glycidyl methacrylate 0.00039 
TBMA 0.0039 
Copper (II) Bromide 2.67 x 10-5 
PEG-bromoisobutyrate 1.3 x 10-4 
Tris pyridyl methyl amine 2.61 x 10-5 
Table 7.2: Molar quantities of triblock copolymer synthesis initial solution. 
7.2.2 Post-Micellarization Crosslinking 
The nanogels were then formed by heating a solution of 1 mg/mL of the block copolymers to 
80ºC.  After attaining temperature a solution of 1 mg/mL NH2-PEG-NH2 was injected to 
crosslink the GMA units to form spherical nanogels.      
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7.2.3 Measurement of Micelle formation: DLS 
The effect of temperature on the formation of micelles was measured using a Malvern Zetasizer 
ZS (Malvern, UK). The data were collected by dissolving freeze dried particles in 1 mL of DI 
water and adjusting the temperature by 3ºC increments and then allowed to equilibrate for 60 
seconds.  Temperature was ramped 20ºC to 59ºC and then down to 20ºC 
 
7.2.4 NMR Spectroscopy 
Nuclear magnetic resonance spectra were taken with a NMSR spectrophotometer (model 400 
MHZ, Varian Palo Alto, CA) with a Direct Drive sample changer.  Samples were dissolved in 
deuterated acetone at a concentration of 20 mg/mL. 
7.2.5 DSC 
Modulated DSC studies were performed with a  DSC (Q2000, TA instruments, New Castle, DE).  
Samples were loaded at a minimum weight of 5 mg into aluminum pans and sealed.  Studies 
were run from 20-200ºC in a nitrogen environment. 
7.2.6 TEM Imaging 
Images were obtained on an Transmission Electron Microscope (FEI Tecnai, Hillsboro, OR) 
operating at 80 kV. Carbon coated copper grids (400 mesh) were plasma treated using an 
Emitech Glow Discharge instrument to render them hydrophilic prior to adding 5 µL of the 
nanoparticle suspension. After 30 seconds, the nanoparticle suspension was wicked off using 
Whatman 1 filter paper. The particles were negatively stained by placing a 5 µL drop of the 
staining solution (2% uranyl acetate for the crosslinked micelles, 2% phosophotungstic acid, pH 
8.0 for the polymer-magnetic particle composites) on the particle-coated grid for 30 seconds 
before being wicked off with Whatman 1 filter paper. 
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7.3 Results and Discussion 
7.3.1 Uncrosslinked Micelle Formation 
Figure 7.1 shows the DLS temperature trend of a 1 mg/mL suspension of linear P(EG-b-TBMA-
b-NIMAAm).  At temperatures below the LCST of about 44ºC, the system demonstrates no 
repeatable size.  This point is also where the counts detected by the DLS drop below a potentially 
critical value of 20,000 kilo counts per second (kcps) as seen in Figure 7.2.   
 
Investigation of characteristic intensity peaks and correlation functions from above and below 
the LCST also show a significant change in the quality of data, as seen in Figure 7.3 and 7.4.  
The intensity peak below the LCST is jagged and the correlation function does not demonstrate 
the sigmoidal shape necessary for the DLS to produce accurate measurements of hydrodynamic 
radius.  These results are indicative of polymers that are solubilized in the solution rather than 
spherical nanoparticles.  The characteristic results from above the LCST are seen in Figure 7.4.  
Here, there is a smooth intensity curve and sigmoidal correlation function, signifying low 
polydispersity and spherical morphology.    
 
The NMR results in Figure 7.5 show the presence of PEG, PNIPMAAm, and PTBMA 
characteristic shifts.  The characteristic PNIPMAAm tertiary isopropyl carbon shift and PEG 
ethylene shifts at 3.9 and 4.0, respectively, are present in about equal quantiles signifying a ratio 
of 4:1 NIPMAAm to ethylene glycol units, which is to be expected with the molar quantities of 
these components in the feed.  The exact TBMA incorporation is muddled by the similar shifts it 
shares with PNIPMAAm.  Although its presence can be confirmed from the size of the methyl 
proton peak comparted to the peak of the PNIPMAAm.  Normally this ratio for PNIPMAAm 
alone is 9:1, in this instance this ratio is 10.5:1. 
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7.3.2 Post-Micellerization Crosslinking for Nanogel Formation 
The TEM nicrographs of these nanoparticles are seen in Figure 7.6. These images show spherical 
polymeric nanogels.  Since the micelles only form at temperatures well above room temperature, 
the TEM images prove that the micelles were crosslinked during the crosslinking step.  If they 
were not, the TEM images would show no spherical structures.     
7.4 Conclusions 
Tri-block copolymers have been synthesized and their self-assembling nature characterized with 
DLS. These systems have demonstrated ability to self-assemble in response to increase in 
temperature above the LCST.  They also can be crosslinked after self-assembly to form 
permanent nanogels.      
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Illustration 7.1: Schematic for a general ARGET-ATRP reaction[63]. 
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Illustration 7.2: Micelle formation of tri-block copolymers around a magnetic core. 
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Entry –X R– 
1 –NH2 
 
 
 
 
2 
 
NH2– 
3 –N C O NH2– 
4 –C C–H N3– 
5 –N3 H–C C– 
6 –OH 
 
 
7 –COOH NH2– 
8 
 
HS– 
9 
 
NH2– 
10 –NR2 I– 
  Table 7.1: Functional groups of micelle cross-linkers used to date. Functional group X-on back 
bone of polymer.  Functional group R- disubstituted on cross linker[64].  
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Figure 7.1: Hydrodynamic diameter versus temperature of triblock copolymers.  PEG-b-
PTBMA-b-PNIPMAAm. (N=1) 
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Figure 7.2: DLS kcps versus temperature of PEG-b-PTBMA-b-PNIPMAAm. 
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Figure 7.3: DLS supplemental graphs at 40ºC for PEG-b-PTBMA-b-PNIPMAAm.  A. Intensity 
percent vs. hydrodynamic diameter. B. Correlation coefficient vs. relaxation time.  
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Figure 7.4: DLS supplemental graphs at 45ºC for PEG-b-PTBMA-b-PNIPMAAm.  A. Intensity 
percent vs. hydrodynamic diameter. B. Correlation coefficient vs. relaxation time. 
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Figure 7.5: H
1 
NMR Spectra of P(EG-b-TBMA-b-NIPMAAm) in Acetone.  
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Figure 7.6: TEM micrographs of PEG-b-PTBMA-b-PNIPMAAm micelles crosslinked with 
GMA and NH2-PEG- NH2. 
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CHAPTER 8 
 Conclusions 
 
The development of new systems to improve the localization and increase the toxic threshold of 
chemotherapeutics is necessary to provide oncologists anther tool to help combat the wide array 
of cancerous diseases in the world.  To this end, this thesis has focused on developing and 
improving thermoresponsive polymer nanogels for use in externally triggered nanocomposites.   
 
Passivation was the first hurdle that was addressed in order to develop systems for drug delivery 
in vivo.  The lack of effective strategies for PEG attachment to PNIPAAm nanogels called for 
development of new surface modification processes to surface-localize the PEG tethers.  In order 
to do this, surface hydrolysis was explored as a method to surface modify higher percentages of 
AAm.  Surface hydrolyzed nanogels were examined for incorporation of carboxylic acid 
comonomers to quantify the extent of hydrolysis and the surface localization of the functional 
groups.  The 15% AAm system demonstrated an extent of hydrolysis consistent with surface 
hydrolysis, while 20% AAm exhibited a functional group concentration indicative of hydrolysis 
of the bulk, however results eventually showed that the system still localized most of these 
groups near the surface of the nanogels.  
 
After this, these systems were analyzed by DLS for the effect of surface hydrolysis on the 
swelling response of the P(NIPAAm-co-AAm) nanogels.  Although these systems had varying 
responses to the surface hydrolysis process, neither had their overall swelling response 
negatively affected.   Furthermore, the PEG attachment via an EDC/NHS reaction demonstrated 
significant stealthing in terms of change of zeta potential while still allowing the nanogels to 
maintain their critical temperature response.   
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These systems were further analyzed for their in vitro effectiveness as stealthing agents.  First 
these systems were tested for cytotoxicity against RAW 264.7 macrophages, to ensure that their 
uptake would not result in significant cell death.  These studies proved that at fairly high 
concentrations of up to 1 mg/mL, PNIPAAm nanogels exhibit no cytotoxic effects, and the 
surface hydrolysis process does not impart any toxicity.  This thesis has also proven surface 
hydrolysis PEGylation prevents significant adsorption of BSA, as a model protein for the 
indication of opsonization.  The surface hydrolysis PEGylation has proven an effective means of 
surface modification while also providing a sufficient coating to stealth these systems.   
 
Beyond the passivation, PNIPMAAm based hydrogels were synthesized and their effectiveness 
as externally triggerable delivery vehicles was analyzed.  Copolymers with NIPMAAm were 
analyzed for the impact of the various types of copolymers on the swelling response and shift of 
the LCST.  No general trends were observed based on hydrophilicity or hydrophobicity.  Each 
copolymer limited the rate of temperature response.  Most copolymers also caused a decrease in 
the onset of the response.  This decrease in onset lead to a decrease in the LCST, as they all 
achieved complete syneresis at 50ºC.  Copolymerization with EGPhA, AAm, NVP, and PhMA 
all demonstrated this phenomenon.  The only system to positively affect the LCST is TBMA.  
P(NIPMAAm-co-TBMA) nanogels exhibited an LCST of 46ºC with the sharpest change of any 
of the PNIPMAAm copolymer nanogels. 
 
The P(NIPMAAm-co-TBMA) systems also proved to be more compatible with DOX.  The 
higher partition coefficient and the larger change in the partition coefficient between 37°C and 
45°C signifies the driving force for release from these systems.  Because of a number of factors, 
including volume decrease, .  Due to the impact on both the swelling response and partition 
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coefficients, copolymers with the hydrophobic copolymers demonstrate more favorable 
characteristics than those copolymerized with hydrophilic comonomers.   
Novel core/shell systems were synthesized with a few different copolymers.  These systems were 
characterized, and their structure confirmed with DSC and NMR spectroscopy.  The addition of 
the copolymer shells were shown to have little impact on the LCST of the core, while 
significantly decreasing the overall swelling response.  These Core/shell structures were shown 
to improve drug partitioning, while limiting the release of both DOX and fluorescein.  These 
studies showed the importance of hydrophobicity for drug loading and retention.  In terms of 
loading, PTBMA proved to improve drug-polymer compatibility, however in terms of overall 
drug delivery TBMA has no improvement over PhMA.   
 
In order to address other means for synthesis of these nanocomposites ARGET ATRP was used 
to synthesize schizophrenic triblock copolymers based around PNIPMAAm.  These copolymers 
were then proven to form micelles in response to increases in temperature.    These    micelles 
were then crosslinked to form PEGylated nanogels.  This is a promising method to form 
core/shell nanogels with a PEG corona.     
 
This thesis has developed a number of nanogel systems that could be used for externally 
triggered drug delivery vehicles. It has gone towards addressing two key issues, the 
biocompatibility and factors that affect the polymer/drug interactions.  It has gone further, to 
develop novel systems to create more efficient drug carriers that can be loaded at higher levels 
while limiting the diffusional release that accompanies these systems.  One constant for all 
systems were the beneficial effects of the inclusion of more hydrophobic comonomers.  TBMA 
has proven an effective means to both impart drug compatibility with DOX while also limiting 
its release in vitro.   
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The next step in this work is to combine the successful results in this thesis to produce a full drug 
carrier for in vivo studies.  The surface hydrolyzed nanogels should be examined for their 
circulation half-life in vivo to confirm effectiveness of the surface modification scheme.  Then 
they can be synthesized with iron oxide nanoparticles and characterized for their drug delivery 
efficacy.   
 
The nanogels synthesized with NIPMAAm have yielded two promising candidates for further 
testing, PNIPMAAm/TBMA and PNIPMAAm/PPhMA at 2:1 molar ratios.  In order for these 
systems to be viable for clinical use, they must first be synthesized with a PEG corona.  The 
post-micelle crosslinking scheme provides a robust way to achieve this. However it must be 
accomplished with a variety of the comonomers and used to incorporate a stimuli responsive 
nanoparticle.  Another cross-linking scheme could be selected to incorporate a biodegradable 
scheme to the particles.   If these next steps are successful, these particles could prove viable 
drug delivery vehicles.      
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APPENDIX 
List of Acronyms 
5-FU – 5-Flurouracil 
AA – Acrylic acid 
AAm - Acrylamide  
AMF – Alternating magnetic field 
AMPS - 2-acrylamido-2-methyl-1-propanesufonic acid   
APS – Ammonium Persulfate 
ARGET – activators regenerated by electron transfer 
ATRP – Atom transfer radical polymerization 
DMEM – Dulbecco’s modified eagle’s medium. 
DOPE – Dioleoylphosphatidylethanolamine 
DOX – Doxorubicin 
DSPE – istearoylphosphatidylethanolamine 
EDC - 1-Ethyl-3-(3-dimethylamiopropyl)carbodiimide  
EGPhA – Ethylene glycol phenyl ether acrylate 
ESR – Equilibrium swelling ratio  
𝐸𝑆𝑅 = (
𝑑
𝑑50º𝐶
)
3
EPR – Enhanced permeability and retention effect 
FBS – Fetal bovine serum 
IPN- Inter penetrating network 
ICAR – initiators for continuous activator regeneration 
LCST – lower critical solution temperature 
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MBAM – N’N’- Methylenebisacrylamide 
MNP – Magnetic nanoparticles 
NHS –N-Hydroxysuccinimide 
NIPAAm – N- Isopropyl Acrylamide 
NIPMAm – N-Isopropylmethacrylamide 
NIR – Near infrared laser 
NVP – N-Vinyl pyrrolidone 
PBS – Phosphate buffered saline 
PEG – Polyethylene glycol 
PhMA- Phenyl methacrylate 
RAFT – reversible addition-fragmentation chain-transfer 
RES – Reticuloendotheial system 
SDS – Sodium Dodecyl sulfate  
SEM – Scanning electron microscope 
SPION – Super paramagnetic iron oxide nanoparticles 
TBMA – tert-Butyl methacrylate 
TEM – Transmission electron microscope 
UCST – Upper critical solution temperature 
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